

## Index

Locators in **bold** refer to tables; those in *italic* to figures

*5HT* gene family; *see also* serotonin receptor  
commercially available tests **168**  
single-nucleotide polymorphisms 92, **167**

*ABCB1* gene **165, 167**

abrupt cessation of drugs 172, 174, **184**; *see also* drug discontinuation  
absolute risk reduction, epidemiology 156  
acamprosate **24, 77, 86, 429**, 430–431, 441  
acetylcholinesterase inhibitors (AChIs), cognitive function 376, 489–490, 492, **499**  
acne, adverse drug effects 193  
active comparators, research studies 66  
acute dystonia, adverse drug effects 203  
acute stress disorder 452; *see also* trauma and PTSD  
adaptogens, nutraceuticals 228, **243**  
addiction 439; *see also* alcohol abuse/dependence  
behavioral 438–439, **446**  
cannabis 436  
case vignettes 438  
contingency management 426  
drug toxicology screens, false positives **441**  
measures/assessment 427  
methamphetamine use disorder 436  
opiates 437, 437, **445**  
post-acute withdrawal syndrome 437  
reward pathway disorders 425–427, 426  
stimulant and cocaine addiction 434–436, **443**  
substances of abuse/detection windows **440**  
ADHD (attention deficit hyperactivity disorder); *see also* psychostimulants  
children and adolescents 268, **269**  
cognitive function in adults 493–497  
comorbidity 32, 33  
diagnostic complexity/symptom overlap 27  
effect sizes of differing pharmacotherapies 493  
heritability **150**  
off-label drug uses 13  
placebo effects **86, 87**  
adherence to treatment  
long-acting injectable drugs 368  
outcome mediators 99–100  
polypharmacy 109  
racial/ethnic differences 246  
sex differences 247  
therapeutic drug monitoring 130  
adjustment disorders, antidepressants 283  
adolescents *see* children and adolescents  
*ADRA2A* gene 161  
adrenochrome hypothesis of schizophrenia 224  
adverse drug effects 192–193, 213, 214  
acne 193  
alopecia 193–194  
 $\alpha$  receptor binding affinities in SGAs **196**  
bleeding 194–205  
blood dyscrasias **195, 215**  
bruxism 195  
cardiovascular 195–197  
case vignettes 195, 209  
cause-and-effect relationships 192  
definitions 198  
dementia 198  
differentiating from lack of efficacy 504–505  
differentiating from natural course of illness 287, 309, 310, 501  
discontinuation syndrome 170, 198  
dopamine receptor binding affinities in SGAs **204**  
dry mouth 199  
extrapyramidal side effects 202–203, 203

FGAs vs. SGAs 357–378  
gastrointestinal upsets 199  
hepatic dysfunction 199–200  
histamine receptor binding affinities **212**  
histamine receptor binding affinities of SGAs **205**  
hyperhidrosis 200  
hyperparathyroidism **200, 200**  
hyperprolactinemia 200–201, 201  
kidney damage 197–198  
lupus erythematosus 198–199, **199**  
nephrogenic diabetes insipidus 202  
neuroleptic malignant syndrome 202  
nocebo effect 192, 193  
nutraceuticals **231**  
polypharmacy 108  
QTc interval prolongation 196–197, **196, 197**  
sedation/somnolence 205  
seizures 205  
serotonin receptor binding affinities **212–213**  
serotonin syndrome 205  
sexual dysfunction 206, **216**  
sialorrhea 206  
tolerance optimization **219, 220**  
suicidal ideation 206–207  
SIADH 207  
tardive dyskinesia 207–209, **208, 208**  
tics 210  
tremor 210  
weight gain/obesity 210–213, 213, **217, 218**  
affect, negative symptoms 389–390  
affective disorders *see* mood disorders  
affective instability/lability 308  
borderline personality disorder 470–471  
differential transdiagnostic treatment 31  
psychostimulants 495–497  
transdiagnostic treatment 31, 36, **41**  
age factors/age at onset  
diagnostic complexity/symptom overlap 2  
outcome moderators 94  
aggression, impulsive 336–346, 347; *see also* anger  
anticonvulsants 338, **349**  
antipsychotics 338, 339, **350**  
beta-blockers 340  
intermittent explosive disorder 340–341  
lithium 337–338  
serotonergic drugs **348**  
aggressive dosing *see* high-dosing regimes  
agitated depression 301  
agitation, anxiety disorders signs/symptoms **401**  
akathisia 202, **401**  
alanine aminotransferase (ALT) biomarker 427  
alcohol abuse/dependence 426, 427–428  
acamprosate 429, 430–431, **441**  
addiction 427  
anticonvulsants 429–433  
antidepressants 433, **442**  
antipsychotics 434  
anxiety disorders 433  
baclofen 432  
comorbidity 33  
definitions and terminology 428  
detection windows **440**  
disulfiram 429, 431  
diversity across subpopulations 253  
gabapentin 429, 431–432  
hallucinogens 434  
heritability **150**

- moderation management 428  
 nalfemene 431  
 naltrexone 429–430, **441**  
 novel pharmacotherapies 434  
 off-label drug uses 13  
 ondansetron 432  
 placebo effects **86**  
 Sinclair method 431  
 topiramate 431  
 type A vs. type B alcoholism 428  
 withdrawal effects, treating 428–429
- allele, definition 151–152  
 all-or-nothing thinking, clinician 466  
 alopecia, adverse drug effects 193–194  
 alpha agonists  
   anxiety disorders 402, **413**  
   cognitive function 496  
   trauma/PTSD 457  
 alpha level corrections, false positives 54, **69**  
 alpha nicotinic acetylcholine receptors **376**, 492–493  
 alpha receptor binding affinities, antipsychotics **196**  
 ALT (alanine aminotransferase) biomarkers 427  
 alternative medicine 221; *see also* nutraceuticals  
 amantadine  
   adverse drug effects **216**  
   cognitive function 488, 496  
   counteraction of iatrogenic weight gain **217**  
   hepatically impaired patients **275**  
   OCD 344  
   polypharmacy 117  
   renal patients **278**  
 ambivalence, negative symptoms 389–390  
 amino acid supplements, depression **237**  
 amino acids, NMDA receptors 394–395  
 amisulpride 469, **490**  
 amitriptyline  
   dosage conversions **184**  
   dosing recommendations **322**  
   protein binding **262**  
   serotonin receptor binding affinities **490**  
   therapeutic drug monitoring **141**, **143**  
 amoxapine 248–249, **490**  
 amphetamine  
   avoiding polypharmacy **128**  
   children and adolescents **269**  
   cognitive function 493–494  
   detection windows **440**  
   dosage conversions **188**  
   drug toxicology screens, false positives **441**  
   hepatically impaired patients **275**  
   mechanism of action **21**  
   negative symptoms 394  
   polypharmacy 118  
   protein binding **262**  
   renal patients **278**  
   schizophrenia 375–376  
   stimulant use disorder 434–436  
   therapeutic drug monitoring **143**  
 amygdala 334, 426; *see also* limbic system  
 analysis of variance (ANOVA) statistic 61–62  
 ancestry, definition 245; *see also* racial differences  
 anger 336, 471–472, **472**; *see also* aggression  
 anhedonia **43**, **106**, 289, **390**  
 anorexia nervosa 32, **150**, **236**  
 antepartum depression 253–254; *see also* reproductive psychopharmacology  
 anterior cingulate cortex (ACC), impulsivity 334–335  
 anterior insular cortex 335, 426  
 anterior nuclei, thalamus 335  
 anticholinergics; *see also specific drugs*  
   adverse drug effects 198, 199  
   cognitive function 488  
   FGAs 359  
   geriatric psychopharmacology 248–249, 251  
   anticipation, addiction 426  
   anticonvulsants; *see also specific drugs*  
     adverse drug effects 193–194, **199**, 206  
     alcohol use/dependence 429–433  
     as antipsychotic adjuncts 371–372  
     anxiety disorders **402**, 411, **420–422**  
     borderline personality disorder **481–482**  
     children and adolescents **267**  
     drug discontinuation 177, **183**, **187**  
     hepatically impaired patients **272**  
     impulsive aggression 338  
     lactation **272**  
     mechanism of action **21**  
     multiple pharmacodynamic effects **125**  
     nomenclature/classification **23**  
     non-suicidal self-injury **352**  
     pharmacokinetic drug interactions **121**  
     pregnancy **271**  
     psychotropic profiles **330**  
     renal patients **275**  
     skin excoriation **351**  
     strategies to optimize tolerance **219**  
     suicidal ideation 206  
     trauma/PTSD 458, **463**  
   antidepressants; *see also* MAOIs; SNRIs; SSRIs; tricyclic antidepressants  
     abrupt cessation issues **172–184**  
     ADHD 496  
     adjustment disorders 283  
     adverse drug effects 193–194, 194–205, 206, 207  
     alcohol abuse 433, **442**  
     antidepressant discontinuation syndromes 172–173  
     as antipsychotic adjuncts 372  
     anxiety disorders **302**, **402**, 410, **416**, **417**, **418**  
     augmentation vs. switching strategies 288–289  
     augmentation strategies 289–291, 291–293, **325**  
     bipolar disorder 309, **327**  
     borderline personality disorder **472**, 473–474, **480**  
     bupropion 286, **324**  
     children and adolescents **266**  
     choice of 284–286  
     cocaine addiction **444**  
     cognitive function 489  
     dosage conversions 176–177, **184**  
     dosing recommendations **319**, **320**, **321**, **322**, **323**, **324**  
     drug discontinuation **183**  
     efficacy 284  
     efficacy pharmacogenetics 155  
     geriatric psychopharmacology 248–249, 250–252, **270**  
     hepatically impaired patients **273**  
     lactation **272**  
     multiple pharmacodynamic effects **126**  
     negative symptoms 392, 393  
     nomenclature/classification **23**  
     outcome moderators 93  
     pharmacokinetic drug interactions **120**, **121**  
     pregnancy **271**  
     psychotic depression 300  
     renal patients **276**  
     sex differences 247  
     strategies to optimize tolerance **220**  
     suicidal ideation 206  
     supratherapeutic dosing 286–288, **324**  
     switching vs. augmentation strategies 288–289  
     therapeutic drug monitoring 135, **142**  
     tolerability 285  
     use of SGAs as augmentation strategy 289–291, **325**  
   antihistamines; *see also specific drugs*  
     adverse drug effects 205  
     anxiety disorders **402**, 412  
     cognitive function 488  
     nomenclature/classification **23**  
   antihypertensives, nomenclature/classification **23**  
   anti-inflammatories, as adjuncts 372–373, 373

## INDEX

- antipsychotics; *see also specific drugs*  
adverse drug effects **196, 197, 201, 205**  
alcohol use/dependence **434**  
alpha receptor binding affinities **196**  
antidepressant augmentation/adjuncts **289-291, 325**  
anxiety disorders **402, 411-412, 423-424**  
atypical antipsychotics **356-357**  
augmentation strategies **369, 367-370, 387, 373, 374, 370-375**  
bipolar depression **317**  
bipolar disorder **309-310, 331, 332**  
borderline personality disorder **472, 473, 474-475, 483-484**  
children and adolescents **266**  
cocaine addiction **435-436**  
cognitive rigidity/inflexibility **364**  
conversion to long-acting injectable **186**  
dopamine receptor binding affinities **204, 362-363, 363**  
dopaminergic system **355-356**  
dosage conversions **177, 185**  
dose-response relationships **367**  
dosing recommendations **378, 379-380, 382-385**  
drug discontinuation **183**  
drug interactions **110**  
efficacy of different drugs **364, 365-366**  
extrapyramidal side effects **202-203, 203**  
FGAs vs. SGAs **357-378**  
geriatric psychopharmacology **248-249, 252**  
hepatically impaired patients **274**  
high-dosing regimens **365, 381**  
histamine receptor binding affinities **205, 212**  
HIV/AIDS patients **263**  
impulsive aggression **338, 339, 350**  
lactation **272**  
long-acting injectable **368, 369, 386-387**  
mania **305-306**  
multiple pharmacodynamic effects **127**  
negative symptoms **391, 391-392, 398-399**  
nomenclature/classification **23**  
nonsuicidal self-injury **352**  
vs. placebo **366**  
polypharmacy **116-117, 118, 370**  
pregnancy **271**  
psychotic depression **300**  
racial/ethnic differences **246**  
renal patients **277**  
serotonin receptor binding affinities **212-213**  
short-acting intramuscular injection **367-368**  
strategies to optimize tolerance **220**  
tardive dyskinesia **207-209, 208**  
therapeutic drug monitoring **147, 148**  
trauma/PTSD **458, 464**  
weight gain and obesity **213**
- antisocial personality disorder *see* borderline, histrionic, narcissistic and antisocial personality disorder (cluster B)
- anti-switch vs. anti-recurrence drugs, bipolar disorder **306-308, 307**
- anxiety/GAD **400-401, 414**; *see also* panic disorder; social anxiety disorder  
abortive relief vs. preventative therapy **402-407**  
alcohol use/dependence **433**  
alpha agonists **413**  
anticonvulsants **411, 420-422**  
antidepressants **302, 410, 416, 417, 418, 419**  
antihistamines **412**  
antipsychotics **411-412, 423-424**  
benzodiazepines **402, 403, 404-407, 416**  
beta-blockers **402, 412-413**  
bupropion **418**  
buspirone **402, 403, 407-408**  
cannabidiol **413-414**  
case vignettes **405, 412**  
children and adolescents **268**  
definitions and terminology **355**  
drug discontinuation **177, 187, 191**  
GABAergic system **402-403, 403**  
gepirone **408**  
geriatric psychopharmacology **252**  
HIV/AIDS patients **263**  
lactation **272**  
maintenance vs. drug discontinuation **191**  
measures/assessment **415**  
mineral deficiencies **236**  
mirtazapine **302, 419**  
with mood disorders **301-302, 302, 317**  
nefazodone/trazodone **418**  
off-label drug uses **13**  
outcome moderators **96**  
pharmacotherapy **402, 403**  
placebo effects **86, 87**  
probiotics **243**  
serotonin receptor binding affinities **407-410, 408**  
signs and symptoms **401, 401-402**  
symptoms vs. formal disorders **400-401**  
vilazodone and vortioxetine **408-410**  
Yerkes-Dodson law **400**
- anxiolysis, off-label drug uses **13**
- Apollonian alcoholism **428**
- arginine supplements **237**
- aripiprazole  
 $\alpha$  receptor binding affinities **196**  
antidepressant augmentation/adjuncts **325**  
anxiety disorders **423-424**  
augmentation strategies **373**  
bipolar disorder **331**  
borderline personality disorder **472, 483-484**  
dopamine receptor binding affinities **204**  
dosage conversions **185, 186**  
dosing recommendations **382**  
geriatric psychopharmacology **251-252**  
hepatically impaired patients **274**  
high-dosing regimens **381**  
histamine receptor binding affinities **205, 212**  
impulsive aggression **350**  
long-acting injectable **186, 368, 369, 386-387**  
multiple pharmacodynamic effects **127**  
negative symptoms **398-399**  
protein binding **262**  
renal patients **277**  
research studies **67**  
serotonin receptor binding affinities **212-213, 290, 408, 490**  
short-acting intramuscular injection **367-368**  
therapeutic drug monitoring **143, 148**  
trauma/PTSD **464**
- armodafinil **143, 205**
- arousal states  
alpha agonists **413**  
biomarkers **105-106**  
PTSD **449**  
transdiagnostic treatment **38, 41**
- asenapine  
 $\alpha$  receptor binding affinities **196**  
bipolar disorder **332**  
borderline personality disorder **483-484**  
dosage conversions **185**  
dosing recommendations **382**  
hepatically impaired patients **274**  
histamine receptor binding affinities **205, 212**  
negative symptoms **398-399**  
serotonin receptor binding affinities **212-213, 290, 408, 490**  
therapeutic drug monitoring **148**  
trauma/PTSD **464**
- aspartate aminotransferase (AST) biomarker **427**
- assay sensitivity, research studies **55**
- assessment *see* measurement instruments
- association, genetic **151-152**
- association, negative symptoms **389-390**
- astrological *post hoc* analyses **103**

- atomoxetine  
 children and adolescents **269**  
 cognitive function 495–496  
 drug interactions 110  
 schizophrenia 375–376  
 therapeutic drug monitoring **143**
- attention deficit hyperactivity disorder *see* ADHD
- attentional processing 485, **498**  
 depression 303  
 diagnostic complexity/symptom overlap 27  
 impairments across psychiatric conditions **499**  
 transdiagnostic treatment 36, **41**
- attrition/study dropout, research studies 60–61, **70**
- atypical depression 301
- atypical antipsychotics 356–357
- autism spectrum disorders  
 heritability **150**  
 negative symptoms 389–390  
 probiotics **243**
- autonomic arousal *see* arousal states
- avoidance states, PTSD 449
- avoidant personality disorder (cluster C) 478
- B vitamin deficiencies 224, 227–228
- baclofen, alcohol use/dependence 432
- Bacon, Sir Francis 192
- barbiturates 248–249, **440, 441**
- Bartter–Schwartz criteria, SIADH 207
- baseline severity  
 law of initial value 93  
 outcome moderators 93–94, 97  
 placebo effects 80–81, **81, 93**
- baseline variables, research studies 55
- Bayesian analysis, research studies 57–60
- BDNF* gene **167, 168**
- behavioral addictions 438–439, **446**
- benign ethnic neutropenia (BEN) 246
- benzodiazepines  
 adverse drug effects 198, 205  
 alcohol withdrawal 428–429  
 as antipsychotic adjuncts 375  
 anxiety disorders **402, 403, 404–407, 416**  
 borderline personality disorder 476  
 children and adolescents **268**  
 cognitive function 488  
 detection windows **440**  
 dosage conversions **187**  
 drug discontinuation 177  
 drug interactions **123**  
 drug toxicology screens, false positives **441**  
 effect sizes **403**  
 factors associated with long-term use **416**  
 geriatric psychopharmacology 248–249  
 impulsive aggression 339  
 pregnancy **271**  
 tapering drugs 407, 411, 438  
 trauma/PTSD 455–456
- bespoke treatment *see* precision medicine
- beta-blockers  
 anxiety disorders **402, 412–413**  
 and depression 338  
 impulsive aggression 340  
 trauma/PTSD 456–457
- $\beta$  level corrections, type II errors 54
- bias, cause-and-effect relationships 4
- binge eating disorder 32, 32, **86**
- binge-intoxication 426
- biomarkers of disease  
 alcohol use/dependence 427  
 diagnostic complexity/symptom overlap 26  
 outcome moderators 90–91, 98, **105–106**
- bipolar disorder 305; *see also* depression (bipolar); lithium; mania (bipolar)
- affective instability/lability 308
- antidepressants 309, **327**
- antipsychotics 305–306, 309–310, **331, 332**
- anti-switch vs. anti-recurrence drugs 306–308, 307
- case vignettes 13, 129–130, 170, 174
- children and adolescents **266**
- cognitive function 490–491, **499**
- combination therapy 310–312, **328**
- complex/comorbid presentations 32, 33, 33, 317, **329**
- confounding factors 51–52
- cyclothymic disorder 308
- diagnostic complexity/symptom overlap 27
- differential transdiagnostic treatment 31
- drug discontinuation 170, 174, **190**
- efficacy of lithium for subsequent episodes 11
- heritability **150**
- lamotrigine 312–314, **314**
- maintenance vs. drug discontinuation 180–181, **181, 191**
- measurement-based care 129–130
- mood stabilizers 306–308, 312–314
- off-label drug uses 13
- outcome moderators 96, **106**
- overlapping features with personality disorders 467, 467
- placebo effects 81, **81, 86, 87**
- polypharmacy 108
- premature study dropout levels **70**
- psychostimulants 312
- rapid cycling 314–315, **329**
- relapses 255–256
- research studies 62, 66
- suicidal ideation 50
- transdiagnostic treatment 31
- treatment-emergent affective switch 309–310, 309, **327**
- tweaking drug regimens 9
- bitoperin 396
- bleeding, adverse drug effects 194–205
- blood dyscrasias, adverse drug effects 195, **215**
- blood–brain barrier (BBB), nutraceuticals 225–226, 227–228
- body dysmorphic disorder (BDD) 465
- Bonferroni corrections, statistical significance **69**
- borderline, histrionic, narcissistic and antisocial personality disorder (cluster B) 470–471, 479  
 affective instability/lability 470–471  
 anger 471–472, **472**  
 anticonvulsants **481–482**  
 antipsychotics 474–475, **483–484**  
 benzodiazepines 476  
 case vignettes 477–478  
 coping skills 476  
 depression/antidepressants **473, 473–474, 480**  
 diagnostic complexity/symptom overlap 27  
 distress intolerance 472  
 memantine 476  
 methylphenidate 477  
 mood stabilizers **472, 473, 474**  
 omega-3 fatty acids 476  
 oxytocin 477  
 self-injurious behavior (SIB) 472  
 suicidal ideation 472–473  
 yi-gan san (Chinese herbal medicine) 476
- bottom-up cognition 101, 334
- bound drug fractions 264
- bradycardia, adverse drug effects 195
- brain-gut interactions 229, **243**
- brain regions/connectivity,  
 addiction 426  
 impulsivity/compulsivity 334–335, 334, 342  
 negative symptoms 389, 390  
 psychosis 118  
 trauma 447
- brain volume, trauma/PTSD 447
- Bradford Hill criteria, cause-and-effect relationships **4**

## INDEX

- breast cancer, drug contraindications 247  
 brexanolone, postpartum depression 256  
 brexpiprazole  
    $\alpha$  receptor binding affinities 196  
   antidepressant augmentation/adjuncts 325  
   anxiety disorders 423-424  
   bipolar disorder 331  
   dopamine receptor binding affinities 204  
   dosage conversions 185  
   dosing recommendations 382  
   geriatric psychopharmacology 251-252  
   hepatically impaired patients 274  
   high-dosing regimens 381  
   histamine receptor binding affinities 205, 212  
   impulsive aggression 350  
   negative symptoms 398-399  
   protein binding 262  
   renal patients 277  
   serotonin receptor binding affinities 212-213, 408, 490  
   therapeutic drug monitoring 143  
 bruxism, adverse drug effects 195  
 bulimia nervosa 32, 86, 87  
 buprenorphine 437, 440, 445  
 bupropion 286  
   adverse drug effects 205, 216  
   anxiety disorders 418  
   avoiding polypharmacy 128  
   behavioral addictions 446  
   children and adolescents 269  
   cocaine addiction 444  
   dosage conversions 184  
   dosing recommendations 324  
   drug interactions 110, 120, 123, 124  
   geriatric psychopharmacology 270  
   outcome moderators 97  
   protein binding 262  
   renal patients 276  
   supratherapeutic dosing 324  
   therapeutic drug monitoring 142  
 buspirone  
   adverse drug effects 216  
   anxiety disorders 402, 403, 407-408  
   children and adolescents 268  
   depression 291  
   effect sizes 403  
   serotonin receptor binding affinities 212, 408, 407-408, 490  
   therapeutic drug monitoring 143  
 CACNA1C gene, efficacy pharmacogenetics 167  
 calcium, psychiatric utility of supplements 236  
 calcium channel blockers, adverse drug effects 199  
 candidate gene studies 151-153; *see also* pharmacogenetics  
 cannabidiol (CBD) 226-227  
   anxiety disorders 413-414  
   definition 227  
   drug toxicology screens, false positives 441  
   negative symptoms 397  
   opiate addiction 445  
   schizophrenia 375  
   trauma/PTSD 459  
 cannabis addiction 436  
 carbamazepine  
   adverse drug effects 207, 215  
   alcohol use/dependence 429  
   as antipsychotic adjunct 387  
   anxiety disorders 420  
   avoiding polypharmacy 128  
   bipolar mania 316  
   borderline personality disorder 481-482  
   children and adolescents 267  
   contraindications 170  
   drug interactions 121  
   efficacy pharmacogenetics 155  
   hepatically impaired patients 272  
   impulsive aggression 349  
   indications for 316  
   pregnancy 271  
   protein binding 262  
   psychotropic profiles 330  
   renal patients 275  
   strategies to optimize tolerance 219  
   therapeutic drug monitoring 139, 143  
   trauma/PTSD 463  
   tweaking drug regimens 8  
 carbohydrate deficient transferrin (CDT) biomarker 427  
 Cardenas, Diane 221  
 cardiovascular adverse drug effects 195-197  
 cariprazine  
    $\alpha$  receptor binding affinities 196  
   antidepressant augmentation/adjuncts 325  
   anxiety disorders 423-424  
   bipolar depression 328  
   bipolar disorder 331  
   dopamine receptor binding affinities 204  
   dosage conversions 185  
   dosing recommendations 382  
   hepatically impaired patients 274  
   high-dosing regimens 381  
   histamine receptor binding affinities 205, 212  
   impulsive aggression 350  
   long-acting injectable 368  
   negative symptoms 398-399  
   renal patients 277  
   serotonin receptor binding affinities 212-213, 408, 490  
   therapeutic drug monitoring 143, 148  
 carnosine, cognitive function 492  
 carry-over effects, research studies 52  
 catatonia 301  
 catecholamine hypothesis of mood disorders 12  
 categories vs. dimensions *see* transdiagnostic treatment  
 CATIE trial 89, 364, 365, 491  
 cause-and-effect relationships 3-4  
   adverse drug effects 192  
   Bradford Hill Criteria 4  
   case vignette 5  
   observed effects/outcomes 4-5  
 CBD *see* cannabidiol  
 CDT (carbohydrate deficient transferrin) biomarker 427  
 celiac disease, patients with 261  
 cessation of drugs, abrupt 172, 174, 184; *see also* drug discontinuation  
 changes in drug regimens *see* tweaking drug regimens  
 chemical imbalance hypothesis 12  
 children and adolescents 248  
   anticonvulsants 267  
   antidepressants 266  
   antipsychotics 266  
   anxiolytics 268  
   lithium 266  
   psychostimulants 268, 269  
   trauma outcome moderators 97  
 Chinese herbal medicine 221, 476; *see also* nutraceuticals  
 chirality, drug 178  
 chlorpromazine  
   adverse drug effects 196, 199  
   dosage conversions 185  
   dosing 379-380  
   usefulness 358-359  
 choline, nutraceuticals 241-242  
 cholinergic drugs, schizophrenia 376  
 cholinergic rebound, abrupt cessation of drugs 172  
 cholinergic neurotransmitter systems 16  
 chromium, psychiatric utility of supplements 236  
 chronic major depression 174, 190, 300  
 chronic obstructive pulmonary disease (COPD), and depression 259-260

- chronicity, outcome moderators 94–95  
Church, George M. 149  
Churchill, Sir Winston 107  
cigarette smokers, diversity across subpopulations 252  
citalopram  
  adverse drug effects 196  
  alcohol use/dependence 442  
  compulsive shopping/buying behavior 346  
  dosing recommendations 319  
  geriatric psychopharmacology 270  
  histamine receptor binding affinities 212  
  impulsive aggression 348  
  protein binding 262  
  renal patients 276  
  serotonin receptor binding affinities 212–213  
  supratherapeutic dosing 324  
  therapeutic drug monitoring 140, 143  
citicoline 397, 436  
classification functions, research studies 67, 67; *see also* nomenclature  
Clinical Antipsychotics Treatment Intervention Effectiveness *see* CATIE trial  
clinical assessment approach, cognitive function 487–488  
clinical equipoise, research studies 52  
Clinical Institute Withdrawal Assessment for Alcohol revised (CIWA-Ar) 427  
Clinical Opiate Withdrawal Scale (COWS) 427  
clinically meaningful results, research 54, 56–57  
Clinician-Administered PTSD Scale (CAPS) 450  
clomipramine  
  anxiety disorders 417  
  dosage conversions 184  
  dosing recommendations 322  
  drug interactions 110, 123  
  serotonin receptor binding affinities 490  
  therapeutic drug monitoring 141, 143  
  trichotillomania 345  
clonazepam, anxiety disorders 404–405  
clonidine 269, 445, 457–458  
clozapine  
  abrupt cessation issues 172–184  
   $\alpha$  receptor binding affinities 196  
  antidepressant augmentation/adjuncts 325  
  augmentation strategies 373–374, 374  
  borderline personality disorder 483–484  
  dopamine receptor binding affinities 204  
  dosage conversions 185  
  dosing recommendations 383  
  drug interactions 121, 122, 123  
  high-dosing regimes 381  
  histamine receptor binding affinities 205, 212  
  impulsive aggression 350  
  negative symptoms 398–399  
  polypharmacy 116–117  
  protein binding 262  
  racial/ethnic differences 246  
  renal patients 277  
  serotonin receptor binding affinities 212–213, 290, 408, 490  
  therapeutic drug monitoring 148  
CNTN4 gene 167  
cocaine addiction 434–436  
  antidepressants 444  
  antipsychotics 435–436  
  detection windows 440  
  topiramate 443  
Cochrane's Q parameter 63  
codeine 155, 440  
coefficient of variation, measurement-based care 132  
co-enzyme Q10 241–242  
cognitive function 485, 497; *see also* attentional processing; disorganized thinking;  
  executive function  
  ADHD 493, 493–497  
  affective instability/lability 495–497  
  antidepressants 489  
  biomarkers 105–106  
  bipolar disorder 490–491  
  case vignettes 491  
  clinical assessment approach 487–488  
  dementia 497, 499  
  impairments across psychiatric conditions 499  
  lithium 315–316  
  major cognitive domains 498  
  measurement instruments 486–487  
  memory 485  
  mood disorders 488–490  
  outcome mediators 101  
  practice effects 488  
  as primary treatment target in schizophrenia 375–376  
  procholinergics 489–490  
  pseudospecificity 488–489  
  PTSD 449  
  pyramid model 486, 487  
  schizophrenia 491–493  
  serotonin receptor 489–490, 490  
  subtypes of long-term memory 487  
  therapeutic drug monitoring 144  
cognitive rigidity/inflexibility, antipsychotics 364  
Cohen's d, research studies 56, 58–59  
  cold cognition *see* top-down cognition  
collinearity 92  
combination therapy *see* polypharmacy/combination therapy  
comorbidity 32–34; *see also* diagnostic complexity  
  ADHD 32, 33  
  alcoholism 33  
  anorexia nervosa 32  
  binge eating disorder 32, 32  
  bipolar disorder 33, 33, 329  
  bulimia nervosa 32  
  genetics 33–34, 34  
  psychosis 32, 32  
  substance use disorders 35  
complementary medicine, anxiety disorders 403; *see also* nutraceuticals  
completely missing at random (MCAR), research studies 60  
completer analyses, research studies 60, 61  
complex combination therapy 107; *see also* polypharmacy/combination therapies  
complex presentations *see* diagnostic complexity  
compulsions, definitions 333; *see also* impulsivity/compulsivity  
compulsive shopping/buying behavior 346  
COMT gene 78, 152, 160–161  
Conan Doyle, Sir Arthur 3, 91  
confidence intervals (CIs) 51, 258  
confounding by indication, defined 50; adverse drug effects 198  
confounding factors  
  cause-and-effect relationships 4  
  outcome moderators/mediators 92  
  research studies 51–52  
CONSORT (CONsolidated Standards of Reporting Trials) diagrams, research  
  studies 49, 49  
context processing 470  
contingency management (CM) 426  
controlled drinking, moderation management 428  
Cooper's nomogram 134  
coping skills, borderline personality disorder 476; *see also* resilience  
core mood symptoms 289  
corticolimbic circuitry *see* limbic system  
cortico-striatal-thalamo-cortical circuitry 342  
course of illness  
  diagnostic complexity/symptom overlap 27, 29  
  differentiating adverse effects from 287, 309, 310, 501  
  longitudinal stability 30–31, 43  
course of treatment 7–9  
  drug maintenance vs. discontinuation 179, 180–182  
  two week/20% rule 8  
COVID-19 pandemic, trauma/PTSD 452–453  
Cox proportional hazard models, research studies 65  
creatine 459, 491  
credible intervals, Bayesian analysis 58

## INDEX

- crime scene investigation (CSI) psychiatry 5–6, 26  
 crossover designs, research studies 52, 53  
 cross-tapering 170–171; *see also* tapering drug regimes  
 curvilinear dose-response curves 132  
 cyclothymic disorder 308  
 CYP gene family 161, 165  
 cytochrome P450 system  
   drug interactions 100  
   efficacy pharmacogenetics 155  
   nutraceuticals 231  
   pharmacokinetic pharmacogenetics 154, 155  
   pharmacokinetics 263  
   therapeutic drug monitoring 143
- D-cycloserine, cognitive function 492  
 D-serine, trauma/PTSD 459  
 D vitamin deficiencies 223–224  
   case vignettes 223  
   depression 223–224, 232  
   physiological role 233  
   schizophrenia 223  
   treating low serum levels 224  
 dasotraline, ADHD 496  
 data mining, research studies 63  
 Davidson Trauma Scale 451  
 davunetide (novel neuropeptide) 368  
 deficit states *see* negative symptoms  
 delirium 31–32, 401  
 delusional parasitosis, pimozide 359  
 dementia  
   adverse drug effects 198  
   agitation and aggression 260–261  
   anxiety disorders signs/symptoms 401  
   cognitive function 497  
   differential transdiagnostic treatment 31–32  
   therapeutic drug monitoring 144  
 demographic factors, adherence to treatment 100  
 dependent personality disorder (cluster C) 478  
 dependent (outcome) variables, research studies 55  
 deprescribing *see* drug discontinuation  
 depression, bipolar 308–309, 310  
   antidepressants 309, 327  
   antipsychotics 317  
   evidence-based medicine 310, 311, 328  
   lamotrigine 312–314, 313  
   treatment flow diagram 310  
 depression/MDD; *see also* antidepressants; postpartum depression; treatment-resistant depression  
   agitated 301  
   amino acid supplements 237  
   with anxiety disorders 301–302, 302, 401  
   attentional processing 303  
   atypical 301  
   and beta-blockers 338  
   borderline personality disorder 473–474  
   children and adolescents 266  
   chronic/persistent 300  
   cognitive function 499  
   D vitamin deficiency 223–224, 232  
   drug discontinuation 174, 190  
   drug maintenance vs. discontinuation 181, 191  
   geriatric psychopharmacology 250–252, 270  
   heritability 150  
   indications for pharmacotherapy 283  
   inflammatory-state 303  
   L-methylfolate 228  
   maintenance phase 304–305  
   mineral deficiencies 236  
   noradrenergic symptom cluster 302  
   nutraceuticals 241–242  
   off-label drug uses 13  
   one-carbon donor molecules 227, 227–228  
   outcome moderators 96, 106  
   and physical illness 258–260, 259, 263  
   placebo effects 86, 87  
   premature study dropout levels 70  
   premenstrual/premenstrual dysphoric disorder 256–257  
   probiotics 243  
   psychedelic drugs 304  
   psychotic 300  
   relapse-prevention post ECT 304, 326  
   sex differences 247  
   serotonergic system 291  
   transdiagnostic treatment 31, 41  
 descriptive statistics, research studies 61  
 desipramine  
   alcohol use/dependence 442  
   anxiety disorders 417  
   cocaine addiction 435, 444  
   dosage conversions 184  
   dosing recommendations 322  
   protein binding 262  
   therapeutic drug monitoring 141, 143  
 desvenlafaxine  
   dosing recommendations 320  
   geriatric psychopharmacology 250  
   protein binding 262  
   renal patients 276  
   supratherapeutic dosing 324  
   therapeutic drug monitoring 136–137, 141  
 deutetrabenazine  
   protein binding 262  
   tardive dyskinesia 208  
   therapeutic drug monitoring 143  
 dextroamphetamine  
   half-life of drugs 178  
   OCD 344  
   therapeutic drug monitoring 143  
 dextromethorphan 143, 248  
 DHEA (dehydroepiandrosterone)  
   cognitive function 492  
   negative symptoms 396  
   psychotropic relevance of 238  
 diagnostic complexity 6; *see also* comorbidity; differential diagnosis; *form fruste* conditions; transdiagnostic treatment  
   bipolar disorder 329  
   evidence-based medicine 7  
   heritability of psychiatric disorders 150–151  
   overlapping symptoms domains 41  
   PTSD 449–450  
   and symptom overlap 26–27  
 diagnostic criteria, research studies 48  
 diagnostic errors 30, 466; *see also* differential diagnosis; *form fruste* conditions  
 diazepam 143, 187  
 dietary restrictions, MAOIs 296  
 Dietary Supplement Health and Education Act (DSHEA) 222  
 dietary supplements, definition 222; *see also* nutraceuticals  
 differential diagnosis; *see also* diagnostic complexity  
   affective instability/lability vs. bipolar disorder 31  
   cognitive disorganization 31–32  
   diagnostic complexity/symptom overlap 27, 41  
   negative symptoms vs. depression 31  
 diffusion tensor imaging (DTI) 91  
 digit symbol substitution test (DSST) 487, 487, 488–489  
 dimensions vs. categories *see* transdiagnostic treatment  
 Dionysian alcoholism 428  
 diphenhydramine 143, 255  
 discontinuation syndrome 172, 198; *see also* drug discontinuation  
 disorganized thinking 31–32, 41  
 dispositional optimism, placebo effects 77  
 dissociation, trauma/PTSD 459–460  
 dissociative identity disorder (DID) 460  
 distress, and trauma 448–449  
 distress intolerance

- borderline personality disorder 472
- post-traumatic 39
- and recovery 10
- transdiagnostic treatment 38–39
- withdrawal effects 438
- disulfiram **146**, 429, 431
- divalproex
  - adverse drug effects **215**
  - alcohol use/dependence 429
  - as antipsychotic adjunct **387**
  - anxiety disorders **420**
  - bipolar mania 316
  - borderline personality disorder **481–482**
  - children and adolescents **267**
  - contraindications 170
  - hepatically impaired patients **272**
  - impulsive aggression 338, **349**
  - indications for 316
  - polycystic ovarian syndrome 257
  - pregnancy **271**
  - protein binding **262**
  - psychotropic profiles **330**
  - renal patients **275**
  - research studies 66
  - strategies to optimize tolerance **219**
  - therapeutic drug monitoring **139**
  - trauma/PTSD **463**
  - tweaking drug regimens 8
- diversity across subpopulations 244–245, 265; *see also* children and adolescents; geriatric psychopharmacology; physical illness; reproductive psychopharmacology
  - alcohol use 253
  - cigarette smokers 252
  - racial/ethnic differences 245–247
  - sex differences 247–248
- donepezil **278**, 488, 489–490, **499**
- dopamine receptor binding affinities 362–363, **363**
  - antipsychotics **204**, **363**
  - anxiety disorders **423–424**
  - bipolar disorder **331**, **332**
  - dosing recommendations **382**
  - polypharmacy 117–118
- dopaminergic system **17**
  - addiction 426
  - drug interactions 110
  - negative symptoms 389, 393–394
  - psychosis 355, 355–356, 360, 361–362
  - and serotonergic system 356–357, 391, 391
- DORAs (dual orexin receptor antagonists) **21**
- dorsolateral prefrontal cortex (DLPFC) 334–335
- dose-response relationships 9–10; *see also* high-dosing regimens
  - placebo effects 77
  - lurasidone 367
  - therapeutic drug monitoring 132
- doxepin
  - dosage conversions **184**
  - dosing recommendations **322**
  - hepatically impaired patients **274**
  - protein binding **262**
  - therapeutic drug monitoring **143**
- DRD4* gene **167**, **168**
- dronabinol, addiction 436
- dropout rates, research studies 60–61, **70**
- drug discontinuation 169, 182; *see also* tapering drug regimens; withdrawal effects
  - abrupt cessation advantages 174
  - abrupt cessation issues 172, **184**
  - ain't broke don't fix 175, 503
  - alcohol withdrawal 428–429
  - anticonvulsants 177, **187**
  - antidepressant discontinuation syndromes 172–173
  - antidepressant dosage equivalents 176–177, **184**
  - antipsychotic dosage equivalents 177, **185**
  - art of deprescribing 114–115, 178–179
  - axioms 178–179
  - benzodiazepines 177, **187**, 407
  - case vignettes 170, 174–175, 175–176
  - chirality 178
  - conversion to LAI antipsychotics **186**
  - cross-tapering vs. switching to another drug 170–171
  - exponential half-life elimination 176
  - half-life of drugs 178
  - lack of efficacy 169–170
  - vs. maintenance 179, 180–182, **181**, **191**
  - MAOIs 173
  - placebo effects 84
  - polypharmacy 114–115
  - prior to starting ECT 173–174
  - psychostimulants 177–178, **188**, **189**
  - randomized controlled trials **190**
  - situations requiring 170, **183**
  - switching serotonergic agents 175
- drug interactions; *see also* pharmacokinetic interactions
  - outcome mediators 99–100
  - pharmacodynamic **123**
  - polypharmacy 108–125, **120**, **121**, **122**
  - therapeutic drug monitoring 130
- drug intolerance *see* adverse drug effects
- drug level monitoring *see* therapeutic drug monitoring
- drug response, heritability 150
- drug treatments, general information 3, 15, 500
  - avoiding changes where possible 175, 503
  - backup plans 502–503
  - case vignettes 5, 13, 505
  - cause-and-effect relationships 3–4, **4**
  - caution in use of high-dosing regimens 506
  - changing one variable at a time 500
  - course of treatment 7–8
  - defining goals of treatment 14–15
  - defining recovery 10
  - differentiating effects from lack of efficacy 504–505
  - differentiating effects from natural course of illness 287, 309, 310, 501
  - dose-response relationships 9–10
  - efficacy for subsequent episodes 11
  - gyroscope analogy 10
  - humility in practice 507
  - learning from past experience 503–504
  - mechanism of action 11–12, **21**
  - nomenclature/classification 13–14, **23**
  - objective measures of symptom severity 500–501
  - observed effects/outcomes 4–5
  - "on-label/off-label" uses 12–13
  - patient individuality 7–8
  - pharmaco-archaeology 504
  - phases of drug development 22
  - recognising need to move beyond pharmacological solutions 507
  - retracing steps if problems arise 503
  - risk-benefit analysis of aggressive pharmacology 506–507
  - role of placebo/nocebo effects 505
  - sliding scale approach 505
  - treatment rationale 502
  - tweaking drug regimens 8–9
  - two week/20% rule 8
  - wise use of technology 506
- dry drunk 426
- dry mouth, adverse drug effects 199
- DSM-5 (Diagnostic and Statistical Manual of Mental Disorders), transdiagnostic treatment 36
- duloxetine
  - anxiety disorders **302**, 407, 419
  - cigarette smokers 252
  - dosing recommendations **320**
  - geriatric psychopharmacology 250, **270**
  - impulsive aggression **348**
  - renal patients **276**



## INDEX

- duloxetine (*cont.*)  
  serotonin receptor binding affinities **212-213**  
  therapeutic drug monitoring **141, 143**
- duration of untreated illness (DUI) outcome moderators 95-96
- dysthymic disorder 300
- dystonia, acute 203
- early response to treatment, outcome mediators 101-102
- EBM *see* evidence-based medicine
- ecological fallacy, definition 81
- Ecstasy **440, 459**
- ECT (electroconvulsive therapy) 173-174, 304, **326, 375**
- Edison, Thomas 485
- EEG (electroencephalography) **105-106**
- effect sizes, research studies 53, 56
- efficacy, and drug discontinuation 169-170
- efficacy pharmacogenetics 153, 155-158, **167**
- efficacy vs. effectiveness, research studies 65, 89
- Einstein, Albert 129
- elderly patients *see* geriatric psychopharmacology
- electroconvulsive therapy *see* ECT
- emotional lability *see* affective instability/lability
- emotional processing, outcome mediators 101
- endophenotypes, definition 152
- end-organ monitoring 137, **146**
- enduring response to treatment, outcome mediators 101-102
- enriched study designs 66-67, 103
- epidemiology, absolute risk reduction 156
- errors *see* diagnostic errors
- escitalopram  
  anxiety disorders **302, 407, 416, 419**  
  dosage conversions **184**  
  dosing recommendations **319**  
  efficacy pharmacogenetics 156  
  geriatric psychopharmacology **270**  
  histamine receptor binding affinities **212**  
  inflammatory-state depression 303  
  protein binding **262**  
  renal patients **276**  
  serotonin receptor binding affinities **212-213, 408**  
  skin excoriation **351**  
  supratherapeutic dosing **324**  
  therapeutic drug monitoring **140, 143**
- estrogen, negative symptoms 396
- eszopiclone  
  drug-drug interactions **123**  
  hepatically impaired patients **274**  
  protein binding **262**  
  renal impairment **278**  
  therapeutic drug monitoring **143**
- ethnicity, definition 245; *see also* racial differences
- euphoria, transdiagnostic treatment **41**
- evidence-based medicine (EBM) 6-7; *see also* randomized controlled trials; research studies and statistical analysis  
  bipolar depression 310, 311, **328**  
  vs. compassionate care/pragmatic solutions 500  
  levels of evidence 7  
  nutraceuticals 221-222, 225  
  polypharmacy 108, 111  
  research studies 48
- exaggerated incentive salience 426
- executive function 37, **41, 486, 494-495**; *see also* cognitive function
- expectation bias, placebo effects 76
- exponential dose-response curves 132
- exponential half-life elimination 176
- expressed emotion (EE), outcome mediators 101
- extensive metabolizers (EMs) 154
- external locus of control, placebo effects 77
- externalizing vs. internalizing dichotomy, transdiagnostic treatment 30, **43**
- extraction ratio 264
- extrapyramidal side effects (EPS) 202-203, 203; *see also* tardive dyskinesia  
  FGAs vs. SGAs 357-378  
  racial/ethnic differences 246
- failed trials, research studies 66
- false discovery statistic **69**
- false negatives, research studies 54, 74, 103
- false positives, research studies 54
- familiarity, definition 150; *see also* pharmacogenetics
- family history, diagnostic complexity 27
- family-wise error rate (FWER) 55
- fast-on/fast-off hypothesis, atypical antipsychotics 356
- fat-soluble vitamins **232, 233**
- fear, vs. anxiety disorders 355
- fight-or-flight response 354; *see also* hot cognition
- FINISH mnemonic, antidepressant discontinuation 172-173
- first order kinetics, dose-response curves 132
- five-factor model of personality 35-36, **45**
- fixed-dose research studies 64, 177
- fixed effects, meta-analyses 63
- fixed tapering dose regimen (FTDR), alcohol 429
- flexible dose research studies 64
- fluoxetine  
  adverse drug effects **196**  
  alcohol use/dependence **442**  
  anxiety disorders **302, 416, 419**  
  borderline personality disorder **480**  
  cigarette smokers 252  
  dosing recommendations **319**  
  drug interactions **121**  
  geriatric psychopharmacology **270**  
  histamine receptor binding affinities **212**  
  impulsive aggression **348**  
  multiple pharmacodynamic effects **126**  
  outcome moderators 96  
  protein binding **262**  
  renal patients **276**  
  schizotypal personality disorder 470  
  serotonin receptor binding affinities **212-213**  
  skin excoriation **351**  
  therapeutic drug monitoring **140, 143**
- fluphenazine  
  conversion to long-acting injectable **186**  
  dosage conversions **185**  
  dosing **379-380**  
  therapeutic drug monitoring **147**
- fluvoxamine  
  alcohol use/dependence **442**  
  behavioral addictions **446**  
  borderline personality disorder **480**  
  cigarette smokers 252  
  dosage conversions **184**  
  dosing recommendations **319**  
  drug interactions 110, **123**  
  impulsive aggression **348**  
  multiple pharmacodynamic effects **126**  
  protein binding **262**  
  renal patients **276**  
  serotonin receptor binding affinities **212-213**  
  skin excoriation **351**  
  therapeutic drug monitoring **140, 143**
- fMRI (functional magnetic resonance imaging) 91, **105-106**
- folic acid, nutraceuticals 228
- food, medications best absorbed with/without 131
- form fruste* conditions 5, 25, 29-30
- formal thought disorder (FTD) 31-32
- fornix, impulsivity/compulsivity 335
- 4 As (affect, association, ambivalence and autism), negative symptoms 389-390
- fraction excreted unchanged (Fe) 264
- frequentist statistics, research studies 57
- funnel plots, meta-analyses 64, **71**
- g factor (general cognitive ability) 487; *see also* cognitive function
- GABAergic system  
  adverse drug effects 205  
  anxiety disorders 402-403, 403, 411  
  neurotransmitter systems **19**

- polypharmacy 118, 118  
psychotropic relevance of supplements 237
- gabapentin  
adverse drug effects 205  
alcohol use/dependence 429, 431–432  
anxiety disorders 411, 422  
avoiding polypharmacy 128  
borderline personality disorder 481–482  
children and adolescents 267  
drug discontinuation 177, 187  
drug interactions 110  
hepatically impaired patients 272  
high-risk subgroups 248  
OCD 344  
off-label uses 13  
pregnancy 271  
protein binding 262  
psychotropic profiles 330  
renal patients 264, 275  
stimulant use disorder 435  
strategies to optimize tolerance 219  
trauma/PTSD 463
- GAD (general anxiety disorder) *see* anxiety/GAD
- galantamine 16  
cognitive function 376, 489–490, 492  
effect sizes 499  
hepatically impaired patients 275  
renal patients 278
- gambling, pathological 446
- gaslighting 353, 354
- gastric bypass, patients with 261
- gastrointestinal disorders, patients with 261
- gastrointestinal upsets, adverse drug effects 199
- gatekeeping procedures, research studies 55
- gender dysphoria, diversity across subpopulations 247–248
- general anxiety disorder *see* anxiety/GAD
- general cognitive ability 487; *see also* cognitive function
- generalized estimating equations (GEE) 60, 61
- genetics *see* pharmacogenetics
- Genome-Based Therapeutic Drugs for Depression (GENDEP) project 157
- genome-wide association studies (GWAS) 152–153; *see also* pharmacogenetics
- Genomics Used to Improve Depression Decisions (GUIDED) trial,  
pharmacogenetics 156–157
- genotype, definition 151–152
- gepirone, anxiety disorders 408
- geriatric psychopharmacology 248  
adjunctive strategies 251–252  
antipsychotics 252  
anxiolytics 252  
depression/antidepressants 250–252, 270  
other safety considerations 249–250  
sleep aids 249  
specific drugs/conditions 248–249
- Ginkgo biloba*, effect on cognitive function 497
- glaucoma, patients with 261–262
- glutamate supplements 237
- glutamate receptors 297, 360, 361, 362
- glutamatergic system; *see also* NMDA receptors  
negative symptoms 394–395, 395, 396  
neurotransmitter systems 19  
polypharmacy 118, 118  
psychosis 359–362, 371–372
- glutamyl transferase (GGT) biomarker 427
- glycine, cognitive function 492
- goals of treatment, defining 14–15
- GR1A gene family, commercially available tests 168
- grandiosity, transdiagnostic treatment 41
- GRIN2B gene, efficacy pharmacogenetics 167
- guanfacine 23, 24, 413  
cognitive function 496  
efficacy pharmacology 167, 269  
safety considerations 268
- schizotypal personality disorder 470  
tics 210  
trauma/PTSD 457–458
- gut flora 229, 243
- gyroscope analogy, resilience 10
- H2 blockers, geriatric psychopharmacology 248
- hair pulling 345
- half-life of drugs 176, 178, 385
- hallucinogens 434, 438
- haloperidol  
conversion to long-acting injectable 186  
dosage conversions 185  
schizotypal personality disorder 470  
serotonin receptor binding affinities 490  
therapeutic drug monitoring 143, 147
- halotype, definition 151–152
- Hardy–Weinberg equilibrium (HWE), definition 151–152
- Hawthorne effect 75, 76
- Hedges' *g*, research studies 56, 58–59
- hedonic capacity 101; *see also* anhedonia
- hedonistic behavior, transdiagnostic treatment 41
- Hemingway, Ernest 281
- hepatically impaired patients 261  
adverse drug effects 199–200  
anticonvulsants 272  
antidepressants 273  
antipsychotics 274  
other medications 275  
psychostimulants 275  
safety pharmacogenetics 164  
sedatives 274
- Heraclitus 333
- herbal medicines 221, 239, 240, 476; *see also* nutraceuticals
- heritability; *see also* pharmacogenetics  
definition 150  
drug response 150, 153  
psychiatric disorders 150, 150–153
- heroin, detection windows 440
- heterogeneity, meta-analyses 63
- heterozygote, definition 151–152
- high sensitivity C-reactive protein (hs-CRP) biomarkers 105–106
- high-dosing regimes 10  
antidepressants 286–288  
antipsychotics 365, 381  
caution in use of 506  
risk-benefit analysis 506–507
- hippocampus 334, 447; *see also* limbic system
- Hippocrates 221
- histamine system 20  
adverse drug effects 212  
antipsychotics 205
- historical perspectives, nutraceuticals 221
- histrionic personality disorder *see* borderline, histrionic, narcissistic and antisocial personality disorder (cluster B)
- hit and run drugs, therapeutic drug monitoring 131
- HIV/AIDS, patients with 262–263
- HLA gene family 161, 168
- hoarding behavior, compulsive 346
- Holm–Bonferroni corrections 69
- Hommel-based gatekeeping 55
- homotypic comorbidity 30
- homozygote, definition 151–152
- hope induction, placebo effects 76
- hot cognition 101, 334
- HTR2A gene 160
- human growth hormone (hGH), supplements 238
- humility, principles of psychopharmacology 507
- Hunter's triad, serotonin syndrome 205
- hydralazine 165, 199
- hydrocortisone 155, 440
- hydrocortisone, trauma/PTSD 458–459

## INDEX

- hydromorphone, detection windows **440**  
hydroxyzine **23**  
  anxiety disorders **402, 403, 412**  
  bruxism 195  
  cognitive function 488  
  safety considerations **268**  
hyperarousal *see* arousal states  
hyperhidrosis, adverse drug effects 200  
*Hypericum perforatum* (St. John's wort) **231, 240**  
hyperparathyroidism, adverse drug effects 200, **200**  
hyperprolactinemia, adverse drug effects 200–201, 201, 247, 357–378  
hypersalivation, adverse drug effects 206  
hypersensitivity reactions, discontinuation of drugs 170  
hypertension, abrupt drug cessation **172**  
hypotension, orthostatic 195–196  
hypothalamus, impulsivity/compulsivity 334  
hypotheses, research studies 49, 91, 103
- Icarus pharmacology 118–119, 506; *see also* high-dosing regimes  
illness course *see* course of illness  
illness severity *see* baseline severity  
illness subtype outcome moderators/mediators 98–99, 103  
iloperidone  
   $\alpha$  receptor binding affinities **196**  
  bipolar disorder **332**  
  dopamine receptor binding affinities **204**  
  dosage conversions **185**  
  dosing recommendations **364–383**  
  hepatically impaired patients **274**  
  high-dosing regimes **381**  
  histamine receptor binding affinities **205, 212**  
  impulsive aggression **350**  
  negative symptoms **398–399**  
  protein binding **262**  
  renal patients **277**  
  serotonin receptor binding affinities **290, 408**  
  therapeutic drug monitoring 136, **143, 148**
- imipramine  
  alcohol use/dependence **442**  
  anxiety disorders **417**  
  dosage conversions **184**  
  dosing recommendations **322**  
  geriatric psychopharmacology **270**  
  outcome moderators 96  
  protein binding **262**  
  serotonin receptor binding affinities **490**  
  therapeutic drug monitoring **141, 143**
- Impact of Events Scale (IES) 451  
impulsivity/compulsivity 333–334, 336–346, 347; *see also* aggression (impulsive); OCD  
  in affective and psychotic disorders 336  
  brain regions/networks 334–335  
  case vignettes 340  
  corticolimbic loop 334  
  cortico-striatal-thalamo-cortical dysfunction 342  
  definitions and terminology 333, 335  
  nonsuicidal self-injury 345, **352**  
  obsessive-compulsive phenomena 341–344, **351**  
  other disorders of 345–346  
  salience network 335  
  serotonergic drugs 337, 342–344, **348**  
  skin excoriation 344–345, **351**  
  somatic marker hypothesis 335  
  top-down/bottom-up cognition 334  
  transdiagnostic treatment 37, **41**  
  trichotillomania 345  
  working memory 335
- independent variables, research studies 55  
indication bias, adverse drug effects 198  
indications for pharmacotherapy 6  
individuality, response to medication 7–8; *see also* precision medicine  
inferential statistics, research studies 61  
inflammatory biomarkers, outcome moderators 98  
inflammatory-state  
  depression 303  
  psychosis 372–373, 373  
insight loss, psychosis 38  
insomnia *see* sleep aids  
insula (anterior insular cortex) 335, 426  
intent-to-treat (ITT) samples, research studies 60  
interaction effect, analysis of variance 61  
interleukin-6 (IL-6) biomarkers **105–106**  
intermittent explosive disorder (IED) 340–341; *see also* aggression (impulsive)  
internalizing vs. externalizing dichotomy, transdiagnostic treatment 30, **43**  
internet use disorder 439; *see also* behavioral addictions  
interpersonal factors, outcome moderators/mediators 98, 101  
intramuscular injection (IM), antipsychotics 367–368  
intrinsic clearance 264  
intrusive thoughts, PTSD 449  
ionotropic glutamate receptors 297  
iron supplements **236**  
irritability **41, 336**; *see also* impulsivity/compulsivity  
irritable bowel syndrome 261  
isocarboxazid **24, 142, 321**  
isotretinoin, suicidal ideation 206–207  
izoniazid **165, 199, 234**
- Jadad Scale, research studies 53
- Kava kava (*Piper methysticum*) **231, 240**  
ketamine  
  detection windows **440**  
  mechanism of action 11, **21**  
  NMDA receptors 360  
  randomized controlled trials **326**  
  trauma/PTSD 458  
  treatment-resistant depression 296–300, 299, **326**
- Ketter's hypothesis 312  
kidney damage 197–198; *see also* renal patients  
kindling paradigm 95  
kleptomania 346  
Kruskal-Wallis test, research studies 61–62
- L-arginine **237**  
L-carnosine 492  
L-methylfolate 228  
L-theanine **237, 396**  
laboratory drug monitoring *see* therapeutic drug monitoring  
lactation 255, **272**; *see also* reproductive psychopharmacology  
LAI *see* long-acting injectable antipsychotics  
Laing, R. D. 389  
lamotrigine  
  abrupt cessation issues **172–184**  
  antidepressant augmentation/adjuncts 292  
  as antipsychotic adjunct 371  
  anxiety disorders **420**  
  bipolar depression 312–314, 313, **314, 328**  
  bipolar disorder 307, 312–314, **314**  
  borderline personality disorder **481–482**  
  children and adolescents **267**  
  cognitive function 490  
  drug interactions **121**  
  hepatically impaired patients **272**  
  impulsive aggression **349**  
  OCD 344  
  off-label uses 13  
  placebo effects 81, **81**  
  pregnancy **271**  
  psychotropic profiles **330**  
  renal patients **275**  
  skin excoriation **351**  
  strategies to optimize tolerance **219**  
  therapeutic drug monitoring 134–135, **139**

- trauma/PTSD **463**  
 tweaking drug regimens **8**  
 last observation carried forward (LOCF) **60, 61**  
 lavender, herbal medicines **240**  
 law of initial value **93**  
 leukopenia, adverse drug effects **215**  
 levetiracetam **421, 463**  
 levomilnacipran  
   dosing recommendations **320**  
   geriatric psychopharmacology **250**  
   protein binding **262**  
   renal patients **276**  
   therapeutic drug monitoring **141, 143**  
 levothyroxine, outcome moderators **96**  
 life events, stressful **10, 448**  
 likeability, pharmacotherapy **406**  
 likelihood-based models, research studies **60**  
 limbic system; *see also* amygdala, hippocampus  
   impulsivity/compulsivity **334-335**  
   negative symptoms **389, 390**  
   psychosis **118, 354-356**  
 linear dose-response curves **132**  
 linear pharmacokinetics **131-132**  
 linear regression models **62**  
 Linehan, Marsha **465**  
 linkage disequilibrium (LD), definition **152**  
 lisdexamfetamine **111, 494**  
 literature of psychopharmacology *see* research studies  
 lithium **200, 315**  
   abrupt cessation issues **184**  
   adverse drug effects **193, 197-198, 199, 200**  
   as antidepressant adjunct **291**  
   as antipsychotic adjunct **387**  
   anti-switch vs. anti-recurrence drugs **307**  
   avoiding polypharmacy **128**  
   behavioral addictions **446**  
   case vignettes **5, 174**  
   children and adolescents **266**  
   cognitive effects **315-316**  
   confounding factors **51-52**  
   drug discontinuation **174, 183, 190**  
   drug interactions **111, 123, 124**  
   efficacy for subsequent episodes **11**  
   geriatric psychopharmacology **250**  
   HIV/AIDS patients **263**  
   impulsive aggression **337-338**  
   increased WBC production **215**  
   indications for **315**  
   low-dose **316**  
   maintenance vs. discontinuation **180-181, 181**  
   mechanism of action **21**  
   multiple pharmacodynamic effects **125**  
   number of episodes **95**  
   outcome moderators **98**  
   practical considerations **330**  
   pregnancy **271**  
   relapse-prevention post ECT **326**  
   renal patients **264, 275**  
   strategies to optimize tolerance **219**  
   therapeutic drug monitoring **131, 134, 139**  
   tweaking drug regimens **8**  
 lithium orotate **225**  
 liver problems *see* hepatically impaired patients  
 LOCF (last observation carried forward) **60, 61**  
 locus, definition **152**  
 logical fallacy phenomenon **4**  
 long-acting injectable (LAI) antipsychotics **67, 186, 368, 369, 386-387**  
 longitudinal stability **30-31, 43**; *see also* course of illness  
 long-term memory, subtypes **487**  
 lorazepam **211**  
 lorazepam, dosage conversions **187**  
 low-dose lithium **316**  
 loxapine **185, 379-380, 490**  
 LSD (lysergic acid diethylamide) **434, 440, 441**  
 lumateperone  
    $\alpha$  receptor binding affinities **196**  
   bipolar depression **328**  
   bipolar disorder **332**  
   dosing recommendations **383**  
   hepatically impaired patients **274**  
   high-dosing regimes **381**  
   histamine receptor binding affinities **205**  
   protein binding **262**  
   psychosis **363**  
   renal patients **277**  
 lupus erythematosus, adverse drug effects **198-199, 199**  
 lurasidone  
    $\alpha$  receptor binding affinities **196**  
   antidepressant augmentation/adjuncts **325**  
   anxiety disorders **423-424**  
   bipolar depression **328**  
   bipolar disorder **332**  
   cognitive function **489, 490-491**  
   dosage conversions **185**  
   dose-response relationships **367**  
   dosing recommendations **384**  
   high-dosing regimes **381**  
   histamine receptor binding affinities **205, 212**  
   off-label uses **13**  
   renal patients **277**  
   serotonin receptor binding affinities **212-213, 290, 408, 490**  
   therapeutic drug monitoring **143**  
   luteal phase dosing **256, 257**  
 magnesium supplements **236**  
 main effect, analysis of variance **61**  
 maintenance medication **180-182, 191**  
   bipolar disorder **181**  
   depression **304-305**  
   schizophrenia **376, 388**  
 major depressive disorder *see* depression/MDD  
 major depressive disorder with mixed features (MDD-MF) **13, 317-318**  
 mamillary bodies **334**  
 manganese supplements **236**  
 mania, bipolar **305-306**; *see also* lithium  
   anxiety disorders signs/symptoms **401**  
   carbamazepine **316**  
   divalproex **316**  
   other anticonvulsants **316, 330**  
 MAO-A gene **78**  
 MAOIs (monoamine oxidase inhibitors)  
   abrupt cessation issues **172-184**  
   anxiety disorders **418**  
   borderline personality disorder **473-474**  
   dietary restrictions **296**  
   dosing recommendations **321**  
   drug discontinuation **173**  
   drug interactions **112-113, 124**  
   hepatically impaired patients **273**  
   outcome moderators **106**  
   renal patients **276**  
   strategies to optimize tolerance **220**  
   therapeutic drug monitoring **142**  
   treatment-resistant depression **294, 295, 295-296**  
 maprotiline **24, 490**  
 marijuana, detection windows **440**  
 Maslow's hierarchy of needs **452**  
 maxims of psychopharmacology *see* drug treatments  
 MBC *see* measurement-based care  
 MC4 gene **168**  
 MDD-MF *see* major depressive disorder with mixed features  
 MDMA (3,4-methylenedioxyamphetamine) **440, 459**  
 medication, stopping *see* drug discontinuation  
 measurement-based care (MBC) **129-130, 138**  
   case vignettes **129-130**  
   definitions **130-131**

## INDEX

- measurement-based care (MBC) (*cont.*)  
 experimental measures 137–138  
 objective measures of symptom severity 500–501  
 secondary outcomes 137, **144**  
 serum drug monitoring *see* therapeutic drug monitoring
- measurement instruments  
 addiction 427  
 anxiety disorders **415**  
 cognitive function 486–487  
 negative symptoms in schizophrenia **390**  
 PTSD 450–451
- mechanism of drug action 11–12, **21**; *see also* neurotransmitter systems
- Medawar, Peter 73
- mediators of treatment outcomes *see* outcome moderators/mediators
- medically unexplained physical symptoms (MUPS) 258
- melatonin  
 neurotransmitter systems 20  
 psychotropic relevance of supplements **238**
- memantine  
 alcohol use/dependence 434  
 borderline personality disorder 476  
 cognitive function 492, 496, **499**  
 OCD 344  
 schizophrenia 376
- memory 485, 487; *see also* working memory  
 mesocortical circuitry *see* limbic system
- meta-analyses 63–64  
 funnel plots 64  
 network 63–64  
 pitfalls **71**
- metabolic dysregulation, drug effects 210–213, 213
- metabotropic glutamate receptors 297, 360, 361, 362
- methadone  
 adverse drug effects **196**  
 detection windows **440**  
 drug toxicology screens, false positives **441**  
 opiate addiction 437, **445**  
 therapeutic drug monitoring **143**
- methamphetamine use disorder 436
- methylenedioxymethamphetamine *see* MDMA
- methylphenidate  
 borderline personality disorder 477  
 children and adolescents **269**  
 cognitive function 493–494  
 dosage conversions **189**  
 drug interactions 111  
 geriatric psychopharmacology 251–252  
 half-life of drugs 178  
 hepatically impaired patients **275**  
 long-acting formulations 494  
 protein binding **262**  
 renal patients **278**  
 schizophrenia 375–376
- methylfolate supplements 228
- microbiome, brain-gut interactions 229, **243**
- mineral deficiencies 225, **236**; *see also* nutraceuticals
- Mini-Mental Status Exam (MMSE) 486
- minocycline **199**, 303, 396
- mirtazapine  
 adverse drug effects **216**  
 alcohol use/dependence **442**  
 antidepressant adjuncts 292  
 anxiety disorders 302, **419**  
 cigarette smokers 252  
 cognitive function 488  
 dosage conversions **184**  
 dosing recommendations **323**  
 drug interactions 111, **123**  
 geriatric psychopharmacology **270**  
 hepatically impaired patients **273**  
 histamine receptor binding affinities **212**  
 impulsive aggression **348**  
 multiple pharmacodynamic effects **126**  
 OCD 344  
 protein binding **262**  
 renal patients **276**  
 serotonin receptor binding affinities 212–213, **408, 490**  
 sex differences 247  
 suprathreshold dosing **324**  
 therapeutic drug monitoring **142, 143**
- missing at random (MAR), research studies 60
- mixed effect models, meta-analyses 63
- mixed models for repeated measures (MMRM) 60, 61
- MMSE (Mini-Mental Status Exam) 486
- moclobemide  
 dosage conversions **184**  
 dosing recommendations **321**  
 geriatric psychopharmacology **270**  
 therapeutic drug monitoring **142, 143**
- modafinil  
 avoiding polypharmacy **128**  
 children and adolescents **269**  
 cognitive function 492, 494–495  
 to counter sedation 205  
 drug interactions 111, **124**  
 hepatically impaired patients **275**  
 off-label uses 13  
 protein binding **262**  
 renal patients **278**  
 schizophrenia 376
- moderation management, controlled drinking 428
- moderator analyses, research studies 62–63
- moderators of treatment outcomes *see* outcome moderators/mediators
- monoamine oxidase inhibitors *see* MAOIs
- Montreal Cognitive Assessment (MoCA) 486
- mood disorders 281–283, 318; *see also* bipolar disorder; depression; major depressive disorder with mixed features  
 adjustment disorders 283  
 with anxiety disorders 301–302, 302, 317  
 catatonia 301  
 cognitive function 488–490  
 cyclothymic disorder 308  
 dimensions of **282**  
 emotional lability/affective instability 308  
 impulsivity/compulsivity 336  
 PTSD 449
- mood stabilizers  
 as antipsychotic adjuncts 370–371, 387  
 anti-switch vs. anti-recurrence drugs 306–308  
 borderline personality disorder 472, 473, 474
- mood swings  
*see* affective instability/lability
- morphine, detection windows **440**
- MTHFR* gene 162, **168**
- multiple diagnoses, cause-and-effect relationships 5
- multiple imputation methods, research studies 60
- multiple regression models 62
- multivariate analyses, research studies 61
- muscarinic procholinergics 293
- myocardial infarction, and depression 258
- myocarditis, adverse drug effects 195
- nabilone 436
- N-acetyl-cysteine (NAC)  
 addiction 436  
 behavioral addictions **446**  
 cognitive function 492  
 nutraceuticals **241–242**  
 skin excoriation 351  
 trauma/PTSD 459
- nadolol 340
- nalfemene 431, 446
- naltrexone  
 addiction 426

- alcohol use/dependence 429, **441**  
behavioral addictions **446**  
dysphoria 430  
kleptomania 346  
opiate addiction **445**  
Sinclair method 431
- narcissistic personality disorder *see* borderline, histrionic, narcissistic and antisocial personality disorder (cluster B)
- NaSSAs (noradrenergic and specific serotonergic antidepressants) 372
- NAT2* gene **165**
- natural course of illness *see* course of illness
- naturalistic designs, research studies 50  
necessary clinical adjustments (NCAs) *9*; *see also* tweaking drug regimens
- needs hierarchy, Maslow's 452
- nefazodone  
anxiety disorders 302, **418**  
dosage conversions **184**  
dosing recommendations **323**  
protein binding **262**  
serotonin receptor binding affinities **408**  
therapeutic drug monitoring **142, 143**
- negative affect, addiction 426
- negative predictive value (NPV), research studies **67**
- negative symptoms in schizophrenia 389, 397  
4 As of **389–390**  
amphetamine 394  
antidepressants 392, 393  
antipsychotics 391–392, **398–399**  
cannabidiol 397  
citicoline 397  
corticolimbic circuitry 389, 390  
dehydroepiandrosterone 396  
dopaminergic system 389, 391, 391, 393–394  
estrogen 396  
measures/assessment **390**  
NMDA receptors 394–395, 395  
other medications targeting glutamatergic system 396  
oxytocin **396**  
pregnenolone with L-theanine 396  
pro-dopaminergic drugs 393–394  
serotonergic system 391, 391, 397  
testosterone 397  
transdiagnostic treatment 31
- negative trials, research studies 66
- nephrogenic diabetes insipidus (NDI) 202
- network meta-analyses 63–64
- neurobiological perspectives  
pharmacogenetic test results 158  
placebo effects 78  
transdiagnostic treatment 35–36
- neuroimaging biomarkers **105–106**
- neuroleptic malignant syndrome (NMS) 202
- neuroscience-based drug nomenclature (NbN) 14, **24**
- neuroticism, placebo effects 77
- neurotoxicity/neuroprotection, FGAs vs. SGAs 357–378
- neurotransmitter systems  
cholinergic system **16**  
dopaminergic system **17**  
GABA/glutamate System **19**  
histamine system **20**  
mechanism of drug action 11–12  
melatonin and orexin systems **20**  
noradrenergic system **19**  
placebo effects 78  
psychotropic relevance of supplements **237**  
serotonergic system **18**
- Newtonian laws of psychopharmacology 9, 82, 180
- niacin deficiency, schizophrenia 224
- nicotinic acetylcholine receptors 376, 492–493
- Nietzsche, Friedrich 47, 447
- NIMH Collaborative Depression Study 180
- NIMH Research Domain Criteria (RDoC) 35, **44**
- NMDA receptors  
alcohol use/dependence 434  
cognitive function 492  
drugs targeting 376, 394–395; *see also* ketamine  
negative symptoms 394–395  
psychosis 359–362
- nocebo effect 76, 77–78, 82–84, **87**, 192, 193, 505
- nomenclature  
case vignettes 13  
drug treatments **13–14, 23**  
neuroscience-based 14, **24**
- nominal p-values, statistical significance 55
- nomograms, therapeutic drug monitoring 133–134, **134**
- nonadherence to treatment *see* adherence to treatment
- noninferiority, research studies 55, 56
- nonlinear pharmacokinetics 131–132
- non-nucleoside reverse transcriptase inhibitors **263**
- nonparametric tests, research studies 50–51, 69
- non-suicidal self-injury (NSSI) 345, **352**  
borderline personality disorder 472  
transdiagnostic treatment **41**
- noradrenergic symptom clusters, depression 302
- noradrenergic system **19**
- norepinephrine reuptake inhibitors *see* SNRIs
- normal distribution, research studies 50, 50
- norriptyline  
anxiety disorders **417**  
cognitive function 488–489  
dosage conversions **184**  
dosing recommendations **322**  
geriatric psychopharmacology 251, **270**  
inflammatory-state depression 303  
lactation 255  
protein binding **262**  
relapse-prevention post ECT **326**  
therapeutic drug monitoring **141, 143**
- not otherwise specified (NOS) diagnosis **29**
- novelty seeking, placebo effects 77
- NSSI *see* non-suicidal self-injury
- nucleus accumbens, impulsivity/compulsivity 335
- number needed to treat (NNT) **57**
- number of episodes, outcome moderators 95
- nutraceuticals 221–222, 229, 230; *see also* vitamin deficiencies  
adaptogens 228, **243**  
anxiety disorders **403**  
blood-brain barrier 225–226, 227–228  
cannabidiol 226–227  
case vignettes 229  
definitions 227, 229  
dietary supplements definition 222  
evidence-based medicine 221–222, 225  
herbal medicines **239, 240**  
historical perspectives 221  
L-methylfolate 228  
mineral deficiencies 225, **236**  
negative symptoms 396, 397  
neurotransmitters **237**  
one-carbon donor molecules 227–228  
other compounds **241–242**  
probiotics 229, **229, 243**  
racial/ethnic differences **246**  
repletion/replenishment concept 223  
safety concerns 222–223, **231**  
serotonin synthesis **226**  
sleep aids 228  
steroid supplements **238**
- obesity *see* weight gain and obesity
- objective measures of symptom severity 500–501; *see also* measurement-based care
- observational designs, research studies 6, 50
- observed cases, research studies 60, 61

## INDEX

- observed effects, cause-and-effect relationships 4–5  
observer effect 75  
obsessions; *see also* impulsivity/compulsivity; OCD  
  anxiety disorders signs/symptoms **401**  
  definitions 333  
  vs. psychosis 38  
Obsessive-Compulsive Drinking Scale 427  
obsessive-compulsive personality disorder (cluster C) 478  
OCD (obsessive-compulsive disorder) 341–344; *see also* impulsivity/compulsivity  
  with bipolar disorder 317  
  placebo effects **87**  
  predictors/risk factors for postpartum depression 254  
  skin excoriation 344–345, **351**  
odds ratios (ORs), research studies 51  
olanzapine  
   $\alpha$  receptor binding affinities **196**  
  antidepressant augmentation/adjuncts **325**  
  anxiety disorders **423–424**  
  behavioral addictions 446  
  bipolar disorder **332**  
  borderline personality disorder **483–484**  
  cigarette smokers 252  
  conversion to long-acting injectable **186**  
  dopamine receptor binding affinities **204**  
  dosage conversions **185**  
  dosing recommendations **384**  
  hepatically impaired patients **274**  
  high-dosing regimens **381**  
  histamine receptor binding affinities **205, 212**  
  impulsive aggression **350**  
  long-acting injectable (LAI) **386–387**  
  negative symptoms **398–399**  
  protein binding **262**  
  renal patients **277**  
  serotonin receptor binding affinities 212–213, **290, 408, 490**  
  sex differences 247  
  short-acting intramuscular injection 367–368  
  therapeutic drug monitoring **143, 148**  
  trauma/PTSD **464**  
olanzapine/fluoxetine combination (OFC) 295  
old age/older adults *see* geriatric psychopharmacology  
omega-3 fatty acids **241–242, 476**  
omnibus test, research studies 51  
"on-label/off-label" drug treatments 12–13  
ondansetron 397, 426, 432  
one in ten rule, regression models **62**  
one-size-fits-all approach, efficacy vs. effectiveness 89  
one-carbon donor molecules 227–228  
one-tailed tests, research studies 55–56  
open-label placebos 82  
opiates  
  addiction **437, 445**  
  drug toxicology screens, false positives **441**  
  metabolism 437  
opioid antagonists  
  nonsuicidal self-injury/self-injurious behavior **352**  
  skin excoriation **351**  
optimism, dispositional 77  
oral loading strategies, therapeutic drug monitoring 133–134  
orbitofrontal cortex (OFC) 335  
orexin neurotransmitter system **20**  
orthostatic hypotension, adverse drug effects 195–196  
Osler, Sir William 89  
osmotic-release oral delivery system (OROS) formulation, methylphenidate 494  
outcome measures *see* measurement instruments  
outcome moderators/mediators 89, 99, 104  
  adherence to treatment 99–100  
  age factors/age at onset 94  
  baseline anxiety disorders 97  
  bespoke treatment 90, 93  
  biomarkers as moderators 90–91, **105–106**  
  case vignettes 99  
  changing one variable at a time 500  
  childhood trauma 97  
  chronicity 94–95  
  cognitive function/emotional processing 101  
  confounding factors 92  
  definitions 90  
  diffusion tensor imaging 91  
  drug interactions 99–100  
  duration of untreated illness 95–96  
  early and enduring response to treatment 101–102  
  efficacy vs. effectiveness 89  
  expressed emotion 101  
  genetics 98  
  hedonic capacity 101  
  illness severity 93–94  
  illness subtype 98–99  
  inflammatory biomarkers 98  
  number of episodes 95  
  past treatment responses 97–98  
  patient preferences 98  
  post hoc analyses 103  
  pregnancy 101  
  psychosocial factors 98  
  racial/ethnic differences 96  
  resilience 97  
  sex differences 96  
  for specific conditions **106**  
  suicidal ideation 96  
  substance misuse 101  
  tweaking drug regimens 102–103  
  Wilder's law 93  
outcome variables, research studies 55  
outcomes, primary/secondary 64–65, 72  
overdose, toxicity states 170  
oversimplifications, chemical imbalance hypothesis 12  
oxcarbazepine  
  alcohol use/dependence 429  
  borderline personality disorder **481–482**  
  children and adolescents **267**  
  hepatically impaired patients **272**  
  impulsive aggression **349**  
  psychotropic profiles **330**  
  renal patients **275**  
  trauma/PTSD **463**  
oxytocin  
  borderline personality disorder 477  
  negative symptoms 396  
  schizophrenia 376  
  trauma/PTSD 458  
paliperidone  
   $\alpha$  receptor binding affinities **196**  
  antidepressant augmentation/adjuncts **325**  
  bipolar disorder **332**  
  borderline personality disorder **483–484**  
  conversion to long-acting injectable **186**  
  dosage conversions **185**  
  dosing recommendations **384**  
  hepatically impaired patients **274**  
  high-dosing regimens **381**  
  histamine receptor binding affinities **212**  
  impulsive aggression **350**  
  long-acting injectable **386–387**  
  negative symptoms **398–399**  
  protein binding **262**  
  renal patients 264, **277**  
  serotonin receptor binding affinities **212–213, 290, 490**  
panic attacks 412  
panic disorder; *see also* anxiety/GAD  
  anxiety disorders signs/symptoms **401**  
  buspirone 408  
  heritability **150**

- maintenance of pharmacotherapy 181–182  
 MAOIs **418**  
 outcome moderators 96, 99  
 placebo effects **86, 87**  
 research studies 61  
 PANSS Negative Symptom Factor **390**  
 Papez circuit 354; *see also* limbic system  
 parachutes analogy 222  
 paradoxical injunction, placebo effects 77–78  
 paralimbic structures, impulsivity/compulsivity 335  
 parallel designs, research studies 52  
 parametric tests, research studies 50–51, 69  
 paranoia  
   anxiety disorders signs/symptoms **401**  
   transdiagnostic treatment **41**  
 paranoid personality disorder 468–470  
 Parkinsonism, adverse drug effects 202  
 Parkinson's disease 248, 264  
 paroxetine  
   alcohol use/dependence **442**  
   anxiety disorders **302, 416, 419**  
   behavioral addictions **446**  
   cognitive function 488  
   dosing recommendations **319**  
   geriatric psychopharmacology 250, **270**  
   histamine receptor binding affinities **212**  
   lactation 255  
   personality features 465  
   renal patients **276**  
   serotonin receptor binding affinities **212–213, 408**  
   therapeutic drug monitoring **140, 143**  
   trauma/PTSD 452–453  
 parsimonious drug regimens 115–116, **125, 126, 127, 128**  
*Passiflora incarnata*, herbal medicines **240**  
 past treatment responses, outcome moderators 97–98  
 pathological gambling **446**  
 patient individuality, response to medication 7–8; *see also* precision medicine  
 patient preferences, outcome moderators/mediators 98  
 Pearson, Karl 47  
 peer review, research studies 47  
 perceptual distortions *see* psychosis  
 per protocol analyses, research studies 60, 61  
 perphenazine 358  
   anxiety disorders 411  
   dosage conversions **185**  
   dosing **379–380**  
   therapeutic drug monitoring **147**  
 persistent depressive disorder **174, 190, 300**  
 personality  
   correlates, placebo effects 77–78  
   structural components, transdiagnostic treatment 36  
 personality disorders 465–467, 479; *see also* borderline, histrionic, narcissistic and  
   antisocial personality disorder (cluster B)  
   cluster A 468–470, 479  
   cluster C 478, 479  
   case vignettes 469, 477–478  
   classification 467–468  
   overlapping features with other conditions 466, 467  
   pharmacotherapy 468–470  
 personalized medicine *see* precision medicine  
 PET (positron emission tomography) **105–106**  
 pharmaco-archaeology 504  
 pharmacodynamic drug interactions **123**  
 pharmacodynamic pharmacogenetics 154, **155, 159**  
 pharmacogenetics 149, 162–163; *see also* SNPs  
   *and see specific genes*  
   candidate gene studies 151–153  
   commercially available tests 165, **168**  
   comorbidity 33–34, 34  
   controversies 150, 151, 155, 156, 157  
   cytochrome P450 metabolism 154, **155**  
   definitions 149, 150, 151–152, 158, 159, 161  
   efficacy 153, 155–158, **167**  
   GENDEP project 157  
   genome-wide association studies 152–153  
   GUIDED trial 156–157  
   heritability of drug response 150, 153  
   heritability of psychiatric disorders 150–153  
   neurobiological perspectives 158  
   outcome moderators 98  
   placebo effects 78  
   results interpretation 158, 159, 159–162  
   safety pharmacogenetics 153, **164, 166**  
   schizophrenia 158  
 pharmacogenomics, definition 149  
 pharmacokinetic pharmacogenetics 154  
   cytochrome P450 metabolism 154, **155**  
   enzymes in phase I/phase II hepatic metabolism **164**  
   interpretation of test results 161  
 pharmacokinetics **122**  
   antidepressant combinations **120**  
   antidepressant/anticonvulsant combinations **121**  
   cytochrome P450 system **263**  
   linear and nonlinear pharmacokinetics 131–132  
   non-nucleoside reverse transcriptase inhibitors **263**  
   outcome mediators 99–100  
   protease inhibitors **263**  
   therapeutic drug monitoring 135–137  
 pharmacotherapy *see* drug treatments  
 phases of treatment *see* course of treatment  
 phencyclidine **440, 441**  
 physical illness, psychological sequelae  
   chronic obstructive pulmonary disease 259–260  
   dementia 260–261  
   drug protein binding **262**  
   gastrointestinal disorder 261  
   glaucoma 261–262  
   HIV/AIDS 262–263  
   myocardial infarction **258**  
   Parkinson's disease 264  
   post-stroke depression 258, 258–259  
   psychosis due to 374  
   renal patients 263–264  
   sleep apnea 264–265  
 pimavanserin  
   adverse drug effects **196**  
   antidepressant augmentation/adjuncts **325**  
   dosing recommendations **384**  
   hepatically impaired patients **274**  
   protein binding **262**  
   renal patients **277**  
   serotonin receptor binding affinities **290**  
   therapeutic drug monitoring **143**  
   pimozide 359, 378, **490**  
*Piper methysticum*, herbal medicines **231, 240**  
 placebo-controlled trials 66  
 placebo effects 8, 73–74, 85  
   active vs. inactive 82  
   antipsychotics 366  
   bipolar depression 311, **314**  
   case vignettes 77–78  
   cause-and-effect relationships 3  
   dosing frequency 77  
   drug discontinuation effects 84  
   early and enduring response to treatment **102**  
   illness severity 80–81, **81, 93, 93**  
   neurobiological correlates **78**  
   nocebo effect 76, 77–78, 82–84, **87**  
   open-label placebos 82  
   patient-specific response characteristics 75–76, 76  
   persistence/transience 81–82  
   pharmacogenetic correlates 78  
   prevalence across disorders 80–81, **86**  
   principles of practical psychopharmacology 505



## INDEX

- placebo effects (*cont.*)  
 psychological and personality correlates 77–78  
 regression to the mean 74–75  
 response rates 78–79  
 study designs to minimise 84, 85, **88**  
 trial duration 79–80
- plasma drug level monitoring 130–131; *see also* therapeutic drug monitoring
- pleiomorphic heterogeneity 34
- PMDD *see* premenstrual dysphoric disorder
- Poe, Edgar Allan 425
- polycystic ovarian syndrome 257
- polypharmacy/combination therapies 107, 119  
 adherence to treatment 109  
 aggressive dosing 118–119  
 antipsychotics 116–117, 118, 370  
 bipolar disorder 310–312, **328**  
 complex dopamine model 110  
 continual review of regimens 114  
 definition 107  
 discontinuation of individual components 114–115  
 dopamine agonism/antagonism 117–118  
 drug interactions 108–125, 120, **121**, 122, **123**  
 drug-related problems 108  
 extensive regimens 107–108  
 GABergic system 118  
 MAOIs plus TCAs 112–113, 124  
 parsimonious regimens 115–116, **125**, **126**, **127**, **128**  
 serotonin agonists 113  
 serotonin syndrome 111–112  
 therapeutic drug monitoring 135–137  
 unusual combinations 110–111
- Pomaglometad 362
- poor metabolizers (PMs) 154
- population stratification 152
- positive predictive value (PPV) 67, **67**
- post hoc analyses  
 outcome moderators/mediators 103  
 research studies 51, 62–63
- post hoc ergo propter hoc* phenomenon 4
- post-acute withdrawal syndrome (PAWS) 437
- posterior probabilities, Bayesian analysis 57
- postpartum depression 253–254, **254**, 255, 256; *see also* reproductive psychopharmacology
- post-stroke depression 258–259
- post-traumatic distress intolerance 39
- post-traumatic stress disorder *see* trauma and PTSD
- power, statistical 53–55
- practical psychopharmacology *see* drug treatments
- practice effects, cognitive function 488
- pramipexole  
 cognitive function 491  
 polypharmacy 118  
 protein binding **262**  
 treatment-resistant depression 295
- probiotics 227
- precision medicine; *see also* diversity across subpopulations  
 outcome moderators/mediators 90, 93  
 pharmacogenetics 149–150, 155  
 response to medication 7–8
- predictors of treatment outcome 90; *see also* outcome moderators/mediators
- Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 63
- prefrontal cortex, addiction 426
- pregabalin  
 alcohol use/dependence 429  
 anxiety disorders 403, 407, **422**  
 children and adolescents **267**  
 drug discontinuation 177, **187**  
 drug interactions 110  
 hepatically impaired patients **272**  
 off-label uses 13  
 protein binding **262**
- renal patients **264**, 275  
 strategies to optimize tolerance **219**  
 tapering drugs 411  
 trauma/PTSD **463**
- pregnancy; *see also* reproductive psychopharmacology  
 drug contraindications **170**  
 outcome mediators **101**  
 pharmacotherapy during **254–255**, 271  
 opiates 255
- pregnenolone  
 addiction 436  
 cognitive function 492  
 negative symptoms 396  
 psychotropic relevance of supplements **238**
- premenstrual dysphoric disorder (PMDD) 256
- preoccupation, addiction 426
- primary outcomes, research studies 64–65, 72
- principles of practical psychopharmacology *see* drug treatments (general information)
- prior probability, Bayesian analysis 59
- probiotics **227**, 229, 243
- problem-solving impairments **499**
- processing speed impairments **499**
- procholinergics *see* acetylcholinesterase inhibitors
- pro-dopaminergic drugs, negative symptoms 393–394; *see also* psychostimulants
- progesterone supplements **238**
- proof-of-concept studies 6
- propranolol **128**, 340
- prospective research studies 50
- protease inhibitors, pharmacokinetics **263**
- protein binding, psychotropic medications **262**
- protopathic bias **198**
- pseudobulbar affect (PBA) 249
- pseudospecificity  
 cognitive function 488–489  
 research studies 63
- pseudotranssexualism 248
- psilocybin, substance use disorders 438
- psychedelic drugs, depression 304
- psychological correlates, placebo effects 77–78
- psychopharmacology, practical *see* drug treatments
- psychosis 353–356, 377; *see also* schizophrenia  
 case vignettes 374  
 children and adolescents **266**  
 cognitive rigidity/inflexibility 364  
 comorbidity 32  
 delusional parasitosis 359  
 differential transdiagnostic treatment 31–32  
 dimensional model 38  
 dopaminergic system 355–356, 360, 361–363, 363  
 due to physical illness 374  
 fear vs. anxiety disorders 355  
 gaslighting 353, 354  
 glutamatergic system/NMDA receptors 359–362, 371–372  
 impulsive aggression 338, **350**  
 impulsivity/compulsivity 336  
 limbic system 118, 354–356  
 vs. obsessions 38  
 placebo effects 366  
 top-down/bottom-up cognition 353–354  
 transdiagnostic treatment 37–38, 41  
 treatment goals 353  
 treatment-resistant 373–374, 374, 377
- psychosocial factors, outcome moderators/moderators 98, 101
- psychostimulants; *see also* amphetamine; methylphenidate  
 adverse drug effects 193–194  
 affective instability/lability 495–497  
 antidepressant augmentation/adjuncts 293  
 bipolar disorder 312  
 borderline personality disorder 477  
 children and adolescents 268, 269  
 cognitive function 493–494

- dosage conversions **188, 189**  
drug discontinuation **177-178, 183**  
drug interactions 110, 111, **124**  
executive function 494-495  
geriatric psychopharmacology 251-252  
hepatically impaired patients **275**  
lactation **272**  
long-acting formulations 494  
negative symptoms 393-394  
pharmacological tolerance 495  
pregnancy **271**  
renal patients **278**  
stimulant use disorder 434-436  
therapeutic drug monitoring **142**
- psychotherapy, borderline personality disorder 476  
psychotic depression 300  
PTSD (post-traumatic stress disorder) *see* trauma and PTSD  
PTSD Checklist (PCL) 451  
pyramid model, cognitive function 486, 487
- QTc interval prolongation **196, 196-197, 258**  
antipsychotics 365  
pimozide 378
- quantitative measures *see* measurement-based care  
quercetin, nutraceuticals **241-242**  
quetiapine  
 $\alpha$  receptor binding affinities **196**  
antidepressant augmentation/adjuncts **325**  
anxiety disorders 302, **423-424**  
bipolar depression **328**  
bipolar disorder **332**  
borderline personality disorder **483-484**  
dopamine receptor binding affinities **204**  
dosage conversions **185**  
dosing recommendations **385**  
geriatric psychopharmacology 251-252  
half-life **385**  
hepatically impaired patients **274**  
high-dosing regimes **381**  
histamine receptor binding affinities **205, 212**  
multiple pharmacodynamic effects **127**  
negative symptoms **398-399**  
off-label uses 13  
renal patients **277**  
research studies 62  
serotonin receptor binding affinities **212-213, 290, 408, 490**  
therapeutic drug monitoring **143, 148**  
trauma/PTSD **464**
- racial differences  
antipsychotics 246  
definitions 245  
diversity across subpopulations 245-247  
outcome moderators 96
- rage attacks 41, **336**; *see also* aggression (impulsive)  
raloxefine 238, 492  
ramelteon 249, **274**
- random effects, meta-analyses 63  
randomization, research studies 51-52  
randomized controlled trials (RCTs) 6-7; *see also* evidence-based medicine  
drug discontinuation **190**  
ketamine **326**  
racial/ethnic differences 245
- rapid cycling, bipolar disorder 314-315, **329**  
rapid initial dose escalation (RIDE) strategy 365  
rapid neuroleptization 365  
rating scales *see* measurement instruments  
reality-testing, psychosis 353-354  
reasoning impairments **499**  
rebound hypertension, abrupt drug cessation 172  
receiver operating characteristic (ROC) curves 68  
recovery, and life stresses 10
- redundancy of treatment effects 4, 15, 107, **123, 171, 288, 502-503**  
regression models, research studies 62  
regression to the mean 74-75  
rejection sensitivity 92  
relapses  
course of treatment 180-182  
post ECT 304, **326**  
schizophrenia **388**
- reliability of diagnosis 27-28, **42**  
relief-seeking, addiction 425  
renal patients 263-264  
adverse drug effects 197-198  
anticonvulsants and lithium **275**  
antidepressants **276**  
antipsychotics **277**  
definitions and terminology 264  
other medications **278**  
psychostimulants **278**  
sedatives **278**
- repeated measures, analysis of variance 61  
repletion/replenishment concept, nutraceuticals 223  
reproductive psychopharmacology 253-254  
brexanolone 256  
divalproex and polycystic ovarian syndrome 257  
opiates 255  
pharmacotherapy during lactation 255, **272**  
pharmacotherapy during pregnancy **254-255, 271**  
postpartum depression **253-254, 254, 255, 256**  
predictors/risk factors for depression **254**  
premenstrual dysphoric disorder 256-257  
relapses of existing mood disorders 255-256  
research studies and statistical analysis 47-48, 68  
 $\alpha/\beta$  level corrections 54, **69**  
analysis of variance 61-62  
attrition and study dropout 60-61, **70**  
Bayesian analysis 57-60  
classification functions **67**  
clinically meaningful results 54, 56-57  
Cohen's d/Hedge's g 56, **58-59**  
confounding factors 51-52  
CONSORT diagrams 49, 49  
effect sizes 53, 56  
efficacy vs. effectiveness 65  
enriched designs 66-67  
evidence-based medicine 48  
flexible vs. fixed-dose studies 64  
funnel plots 64  
Jadad Scale 53  
meta-analyses 63-64, **71**  
moderator analyses 62-63  
noninferiority/superiority/sensitivity 55, 56  
normal distribution 50, 50  
number needed to treat 57  
observational vs. naturalistic designs 50  
odds ratios/confidence intervals 51  
one-tailed/two-tailed tests 55-56  
parallel vs. crossover designs 52, 53  
parametric vs. nonparametric tests 50-51, 69  
placebo effects 78-84, 85, 88  
placebo-controlled trials/active comparators 66  
post hoc analyses 51, 62-63  
primary/secondary outcomes 64-65, **72**  
prospective vs. retrospective designs 50  
pseudospecificity 63  
randomization 51-52  
receiver operating characteristic curves 68  
regression models 62  
sample size 54  
sensitivity and specificity 67  
single-group open trials 52-53  
statistical significance and power 53-55  
study design 49-50

## INDEX

- research studies and statistical analysis (*cont.*)  
 study group/study population 48, 49  
 time until event analyses 65  
 type I error/false positives 54  
 type II error/false negatives 54  
 univariate/multivariate analyses 61
- resilience  
 borderline personality disorder 476  
 gyroscope analogy 10  
 outcome moderators 97  
 transdiagnostic treatment 38–39  
 trauma/PTSD 447, 452
- retrospective research designs 50  
 reverse causality 198  
 reward pathway disorders 335, 425–427  
 reward-seeking 425; *see also* addiction  
 risk-benefit analysis, aggressive pharmacology 506–507  
 risky behaviors, transdiagnostic treatment 41
- risperidone  
 adverse drug effects 201  
 antidepressant augmentation/adjuncts 325  
 anxiety disorders 423–424  
 bipolar disorder 332  
 conversion to long-acting injectable 186  
 dopamine receptor binding affinities 204  
 dosage conversions 185  
 dosing recommendations 385  
 drug interactions 111  
 hepatically impaired patients 274  
 histamine receptor binding affinities 205, 212  
 impulsive aggression 350  
 long-acting injectable 386–387  
 multiple pharmacodynamic effects 127  
 negative symptoms 398–399  
 renal patients 277  
 schizotypal personality disorder 469  
 serotonin receptor binding affinities 212–213, 290, 490  
 therapeutic drug monitoring 143, 148  
 trauma/PTSD 464
- ROC *see* receiver operating characteristic curves  
 rumination 333, 401
- SAD (seasonal affective disorder), placebo effects 87  
 s-adenosylmethionine (SAMe) 96, 227–228  
 safety concerns, nutraceuticals 222–223, 231  
 safety pharmacogenetics 153, 166  
 cytochrome P450 metabolism 154, 155  
 enzymes in phase I/phase II hepatic metabolism 164
- St. John's wort, herbal treatments 231, 240  
 salience network, impulsivity/compulsivity 335  
 saturation kinetics 131–132  
 Sayers, Dorothy L. 25  
 Schedule for the Assessment of Negative Symptoms (SANS) 390  
 schizoid personality disorder 468–470  
 schizophrenia; *see also* negative symptoms  
 adrenochrome hypothesis 224  
 augmentation strategies 372, 372–373, 375  
 benzodiazepines 375  
 cannabidiol 375  
 case vignettes 175–176  
 cognition as primary target 375–376  
 cognitive function 491–493, 499  
 D vitamin deficiency 223  
 diagnostic complexity/symptom overlap 27  
 drug discontinuation 175–176  
 drug interactions 111  
 efficacy of different drugs 365–366  
 electroconvulsive therapy 375  
 heritability 150  
 maintenance vs. discontinuation of therapy 191, 376, 388  
 outcome moderators 106  
 pharmacogenetics 158  
 placebo effects 86, 87  
 probiotics 243  
 schizotypal personality disorder 468–470, 491  
 scopolamine, antidepressant augmentation 293  
 Screen for Cognitive Impairment for Psychiatry (SCIP) 486  
 secondary outcomes, research studies 64–65  
 sedation, adverse drug effects 205  
 sedatives; *see also* benzodiazepines; Z-drugs  
 hepatically impaired patients 274  
 pregnancy 271  
 renal patients 278
- seizures  
 abrupt cessation of drugs 172  
 adverse drug effects 205  
 selective serotonin reuptake inhibitors *see* SSRIs  
 selenium supplements 236  
 self-efficacy, placebo effects 77  
 self-injurious behavior (SIB) *see* nonsuicidal self-injury  
 sensitivity, research studies 67  
 SEP-363856 investigational drug 357  
 sequential parallel comparison design studies 85, 88
- serotonergic drugs; *see also* SNRIs; SSRIs  
 adverse drug effects 199  
 borderline personality disorder 480  
 histamine receptor binding affinities 212  
 impulsive aggression 337, 348  
 impulsivity/compulsivity 342–344  
 serotonin receptor binding affinities 212–213  
 switching serotonergic agents 175
- serotonergic system 18; *see also* 5HT gene family  
 anxiety disorders 355  
 atypical antipsychotics 356–357  
 serotonin synthesis 226
- serotonin receptor  
 adverse drug effects 212–213  
 antipsychotic adjuncts 372  
 anxiety disorders 407–410, 408  
 cognitive function 489–490  
 depression 291  
 and dopaminergic system 356–357, 391  
 negative symptoms 397  
 OCD 344  
 polypharmacy 113, 113  
 psychotropic relevance of supplements 237  
 SGAs 290
- serotonin syndrome 111–112, 205
- sertraline  
 adverse drug effects 195  
 alcohol use/dependence 442  
 anxiety disorders 302, 416, 419  
 behavioral addictions 446  
 cocaine addiction 444  
 cognitive function 488–489  
 dosage conversions 184  
 dosing recommendations 319  
 drug interactions 121  
 efficacy pharmacogenetics 156  
 geriatric psychopharmacology 250, 270  
 histamine receptor binding affinities 212  
 impulsive aggression 348  
 lactation 255  
 multiple pharmacodynamic effects 126  
 outcome moderators 96, 99  
 postpartum depression 255  
 protein binding 262  
 renal patients 276  
 serotonin receptor binding affinities 212–213, 408  
 skin excoriation 351  
 suprathreshold dosing 324  
 therapeutic drug monitoring 140  
 trauma/PTSD 452–453  
 serum drug level monitoring, definition 130–131; *see also* therapeutic drug monitoring

- Seuss, Dr. 244  
severity of illness *see* baseline severity  
sex differences  
  diversity across subpopulations 247–248  
  outcome moderators 96  
  PTSD 450  
sexual dysfunction, adverse drug effects 206, 216  
Shakespeare, William 400  
SIADH, adverse drug effects 207  
sialorrhea, adverse drug effects 206  
SIB (self-injurious behavior) *see* nonsuicidal self-injury  
sigmoidal dose-response curves 132  
Sinclair method, alcohol use/dependence 431  
single-group open trials 52–53  
single-nucleotide polymorphisms *see* SNPs  
skin excoriation 344–345, **351**  
SLC gene family 159–160, **167, 168**  
sleep aids  
  geriatric psychopharmacology 249  
  nutraceuticals 228  
  transdiagnostic treatment **41**  
sleep apnea, patients with 264–265  
sliding scale approach to psychopharmacology 505  
SMD *see* standard mean difference  
SNPs (single-nucleotide polymorphisms) 151–153, 152; *see also*  
  pharmacogenetics  
  biomarkers **105–106**  
  commercially available tests **165, 168**  
  comorbidity 34  
  definition 152  
  efficacy pharmacogenetics **167**  
SNRIs (serotonin-norepinephrine reuptake inhibitors); *see also specific drugs*  
  anxiety disorders **417, 419**  
  avoiding polypharmacy **128**  
  dosing recommendations **320**  
  drug interactions **110, 123**  
  geriatric psychopharmacology 250  
  hepatically impaired patients **273**  
  mechanism of action **21**  
  multiple pharmacodynamic effects **126**  
  strategies to optimize tolerance **220**  
  therapeutic drug monitoring **141**  
social anxiety disorder; *see also* anxiety/GAD  
  bupirone 408  
  drug discontinuation **190**  
  MAOIs **418**  
  placebo effects **80, 86**  
social cognition **498**  
  impairments across psychiatric conditions **499**  
  transdiagnostic treatment 37  
sodium benzoate 376, 492  
somatic marker hypothesis 335  
somatic symptom disorder 258  
somatosensory amplification 83  
somnia, adverse drug effects 205  
special populations *see* diversity across subpopulations  
specificity, research studies 67  
spectrum diagnoses, transdiagnostic treatment 29–30  
SSRIs (selective serotonin reuptake inhibitors); *see also specific drugs*  
  abrupt cessation issues **172–184**  
  adverse drug effects 195, 199  
  anxiety disorders **403, 416, 419**  
  bipolar disorder 311  
  cause-and-effect relationships 3  
  dosing recommendations **319**  
  drug interactions **110, 120, 123**  
  effect sizes **403**  
  hepatically impaired patients **273**  
  impulsive aggression **348**  
  impulsivity/compulsivity 336  
  mechanism of action **21**  
  multiple pharmacodynamic effects **126**  
  nonsuicidal self-injury/self-injurious behavior **352**  
  outcome moderators 96, 98  
  placebo effects 76  
  research studies 61  
  strategies to optimize tolerance **220**  
  therapeutic drug monitoring **140**  
  trauma/PTSD 452–455, **462**  
  trichotillomania 345  
stability over time 30–31, **43**; *see also* course of illness  
standard mean difference (SMD), effect size 56, **58–59**  
STAR\*D MDD trials 97, 288–289, 292, 293–294, 301, 336  
State-Trait Anxiety Inventory (STAI) 451  
statins, as antipsychotic adjuncts 373  
statistical power 53–55  
statistical significance 53–55  
statistical tests 50–51, **69**  
statistics, measurement-based care 132–133; *see also* research studies and  
  statistical analysis  
stellate ganglion block, trauma/PTSD 459  
steroidal drugs/supplements **238, 396**  
stimulants *see* psychostimulants  
stopping psychotropic medication *see* drug discontinuation  
stratification, confounding factors 52  
stress; *see also* distress intolerance  
  life events **448**  
  and recovery 10  
  and trauma 448–449  
stroke, post-stroke depression 258–259  
Stroop effect, pharmacogenetics 159  
structural components of personality, transdiagnostic treatment 36  
study design *see* research studies and statistical analysis  
Study to Predict Optimised Treatment in Depression (iSPOT-D) 91  
subpopulations *see* diversity across subpopulations  
substance misuse; *see also* addiction  
  detection windows **440**  
  outcome mediators 101  
  transdiagnostic treatment 35  
subtherapeutic doses, polypharmacy 108  
suicidal ideation  
  adverse drug effects 206–207  
  borderline personality disorder 472–473  
  outcome moderators 96  
  racial/ethnic differences **246**  
  research studies 50  
  transdiagnostic treatment 39–40, 41  
superiority, research studies 55  
supratherapeutic dosing *see* high-dosing regimes  
surface under the cumulative ranking curve (SUCRA), meta-analyses 63–64  
suvorexant  
  hepatically impaired patients **274**  
  protein binding **262**  
  sleep aids 249  
  therapeutic drug monitoring **143**  
sweating, adverse drug effects 200  
symptom-based treatment approaches 28  
symptom overlap **26–27, 41**  
symptom subcomponents, categorical disorders 34–35  
symptom triggered regimen (STR), alcohol withdrawal 429  
syndrome of inappropriate antidiuretic hormone secretion (SIADH), adverse drug  
  effects 207  
synergistic effects, polypharmacy 108, 130  
Syrus, Publius 169  
Szasz, Thomas 353  
  
tachyphylaxis 11, 131  
tamoxifen **122, 155**  
tapering drug regimes *see also* drug discontinuation  
  alcohol withdrawal 428–429  
  benzodiazepines 407  
  cross-tapering vs. switching to another drug 170–171  
tardive dyskinesia **207–209, 208**  
  case vignettes 209  
  FGAs vs. SGAs 357–378  
  VMAT2 inhibition/dopamine supersensitivity 208

## INDEX

- taurine supplements **237**  
 TDM *see* therapeutic drug monitoring  
 TEAS *see* treatment-emergent affective switch  
 temazepam, dosage conversions **187**  
 teratogenic risks of pharmacotherapy 254  
 testosterone  
   negative symptoms 397  
   supplements **238**  
 theanine **237**, 396  
 theory of mind, transdiagnostic treatment 37  
 therapeutic alliance, role in placebo effect 74–75, 83  
 therapeutic drug monitoring (TDM) 129, 130–131, 138, **139**; *see also*  
   measurement-based care  
   antidepressants 135, **142**  
   antipsychotics **147**, **148**  
   case vignettes 136  
   CYP450 inducers and inhibitors **143**  
   definition 131  
   dose-response curves 132  
   end-organ monitoring 137, **146**  
   lamotrigine 134–135  
   linear and nonlinear pharmacokinetics 131–132  
   nomograms 133–134, **134**  
   oral loading strategies 133–134  
   other antidepressants **142**  
   polypharmacy 135–137  
   psychostimulants **142**  
   secondary outcomes 137, **144**  
   SNRIs **141**  
   SSRIs **140**  
   tricyclic antidepressants **141**  
   useful statistics 132–133  
 therapeutic index, pharmacokinetics 132  
 therapeutic range, pharmacokinetics 132  
 therapeutic window, pharmacokinetics 131–132  
 thiopurine methyltransferase, SNPs **165**  
 thioridazine **196**, **379–380**  
 thiothixene **379–380**, 469, 470  
 thrombocytopenia, adverse drug effects **215**  
 thyroid hormone, antidepressant augmentation 292–293  
 tiagabine **421**, 435, **463**  
 tics, adverse drug effects 210, 496  
 timecourse of illness  
   *see* course of illness  
 time until event analyses, research studies 65  
 TNF (tumor necrosis factor) biomarkers **105–106**  
 top-down (cold) cognition 101, 334  
   corticolimbic loop 334  
   psychosis 353–354  
 topiramate  
   alcohol use/dependence 431  
   as antipsychotic adjunct 371–372  
   anxiety disorders **420**  
   avoiding polypharmacy **128**  
   behavioral addictions **446**  
   borderline personality disorder **481–482**  
   children and adolescents **267**  
   cocaine addiction **443**  
   cognitive function 488  
   counteraction of iatrogenic weight gain **217**  
   hepatically impaired patients **272**  
   impulsive aggression **338**, 349  
   OCD 344  
   off-label uses 13  
   pregnancy **271**  
   protein binding **262**  
   psychotropic profiles **330**  
   renal patients 264, 275  
   skin excoriation **351**  
   stimulant use disorder 435  
   strategies to optimize tolerance **219**  
   trauma/PTSD **463**  
   toxicity states 130, 170  
   TPH1 gene **78**, **167**  
   TPH2 gene, commercially available tests **168**  
   tramadol, drug interactions 112  
   transdiagnostic treatment 25–26, 40  
     affective instability/lability 31, 36, **41**  
     arousal states 38, 41  
     attentional processing 36, **41**  
     bipolar disorder 31  
     case vignettes 26  
     cognitive disorganization differential treatment 31–32  
     comorbidity 32–34, 34, 35  
     core transdiagnostic treatment 28–29  
     diagnostic complexity/symptom overlap 26–27, **41**  
     distress intolerance 38–39  
     executive function 37, **41**  
     externalizing vs. internalizing dichotomy 30, **43**  
     first/subsequent episode correlations 30–31, **43**  
     five-factor model of personality 35–36, 45  
     *form fruste* conditions/spectrum diagnoses 29–30  
     homotypic comorbidity 30  
     impulse control 37, **41**  
     negative symptoms vs. depression treatment 31  
     neuroscience-based 35–36  
     NIMH Research Domain Criteria 35, **44**  
     psychosis 37–38  
     reliability/validity 27–28, **42**  
     social cognition/theory of mind 37  
     stability over time/longitudinal stability 30–31  
     structural components of personality perspective 36  
     substance use disorders 35  
     suicidal ideation 39–40, **41**  
     symptom subcomponents 34–35  
     symptom-based treatment approaches 28  
     Tridimensional Personality Questionnaire 36, **46**  
 transgender individuals 247–248  
 trauma and PTSD 447–448, 460, 461  
   acute stress disorder 452  
   alpha agonists 457  
   anticonvulsants 458, **463**  
   antipsychotics 458, **464**  
   benzodiazepines 455–456  
   beta-blockers 456–457  
   case vignettes 449  
   as categorical construct 449–450  
   cognitive therapy 452  
   combination therapy **462**  
   COVID-19 pandemic 452–453  
   diagnostic complexity/symptom overlap 27  
   dissociative illnesses 459–460  
   ketamine 458  
   life events **448**  
   Maslow's hierarchy of needs 452  
   measures/assessment 450–451  
   novel pharmacotherapies 458–459  
   and personality disorders 466  
   pharmacotherapy 454  
   placebo effects **86**, **87**  
   PTSD construct 449–450  
   resilience 447, 452  
   SSRIs 452–455, **462**  
   stellate ganglion block 459  
   stress, distress and trauma 448–449  
   trauma/PTSD 447  
 trazodone  
   adverse drug effects **196**, **216**  
   anxiety disorders **418**  
   cigarette smokers 252  
   cognitive function 488  
   dosage conversions **184**

- drug interactions 111, **123**  
geriatric psychopharmacology **270**  
histamine receptor binding affinities **212**  
postpartum depression 255  
protein binding **262**  
therapeutic drug monitoring **143**
- treatment adherence *see* adherence to treatment  
treatment course *see* course of treatment  
treatment outcomes *see* outcome moderators/mediators  
treatment-emergent affective switch (TEAS), bipolar disorder 309–310, 309, 327  
treatment-resistant conditions  
and accuracy of transdiagnostic treatment 30  
diagnostic errors 466  
GUIDED trial 156–157  
therapeutic drug monitoring 130
- treatment-resistant depression 293–294  
ketamine 296–300, 299, **326**  
MAOIs 294, **295**, 295–296  
olanzapine/fluoxetine combination 295  
pramipexole 295  
staging model **294**
- tree-structured gatekeeping procedures 55  
tremor, adverse drug effects 210  
triazolam, dosage conversions **187**  
trichotillomania 345  
tricyclic antidepressants; *see also specific drugs*  
adverse drug effects **196**, 205  
anxiety disorders **417**  
bipolar depression 308–309  
cognitive function 488  
dosing recommendations **322**  
drug interactions 110, 112–113  
efficacy for subsequent episodes 11  
hepatically impaired patients **273**  
irritable bowel syndrome 261  
multiple pharmacodynamic effects **126**  
racial/ethnic differences 246  
renal patients **276**  
strategies to optimize tolerance **220**  
therapeutic drug monitoring **141**
- Tridimensional Personality Questionnaire (TPQ) 36, **46**  
trifluoperazine, anxiety disorders 411  
triptans, drug interactions 111  
tryptophan, nutraceuticals **241–242**  
tumor necrosis factor (TNF) biomarkers **105–106**  
tweaking drug regimens 8–9  
ain't broke don't fix 175, 503  
bipolar disorder 9  
necessary clinical adjustments, bipolar disorder 9  
Newtonian psychopharmacology 9  
one variable at a time 500  
outcome moderators/mediators 102–103  
twin studies, heritability of psychiatric disorders 151  
two week/20% rule, course of treatment 8  
two-tailed tests, research studies 55–56  
type A vs. type B alcoholism 428  
type I errors, research studies 54  
type II errors, research studies 54, 74, 103
- UGT* gene family **161**, 165  
ultra-rapid metabolizers (URMs) 154  
unbound drug fractions 264  
univariate analyses, research studies 61
- valbenazine  
protein binding **262**  
tardive dyskinesia **208**  
therapeutic drug monitoring **143**, 143
- Valeriana officinalis*, herbal medicines **231**, **240**  
validity of diagnosis 27–28, 42  
valproic acid, HIV/AIDS patients 263  
variable number of tandem repeat (VNTR) 152
- venlafaxine  
anxiety disorders 302, 403, 407, **419**  
dosage conversions **184**  
dosing recommendations **320**  
geriatric psychopharmacology **270**  
outcome moderators 97  
protein binding **262**  
relapse-prevention post ECT **326**  
renal patients **276**  
supratherapeutic dosing **324**  
therapeutic drug monitoring **141**, **143**
- ventral striatum 426  
ventral tegmentum 335  
ventrolateral prefrontal cortex (VLPFC) 335  
ventromedial prefrontal cortex (VMPFC) 335  
verbal fluency, major cognitive domains **498**  
verbal learning impairments **499**
- vilazodone  
anxiety disorders 408–410  
dosing recommendations **323**  
geriatric psychopharmacology 250  
protein binding **262**  
renal patients **276**  
serotonin receptor binding affinities 408–410  
therapeutic drug monitoring **142**, **143**
- visual learning impairments **499**
- vitamin deficiencies; *see also* B vitamin deficiencies; D vitamin deficiencies  
adrenochrome hypothesis of schizophrenia 224  
case vignettes 223  
dosing recommendations **235**  
fat-soluble vitamins **232**, **233**  
psychiatric disorders **232**, **234**  
water-soluble vitamins **234**, **235**
- VNTR (variable number of tandem repeat) 152  
Voltaire (François-Marie Arouet) 73, 500  
volume of distribution 264
- vortioxetine  
adverse drug effects 199  
anxiety disorders 408–410  
cognitive function 488–489  
dosing recommendations **323**  
geriatric psychopharmacology 250  
hepatically impaired patients **273**  
protein binding **262**  
serotonin receptor binding affinities 408–410, **490**  
therapeutic drug monitoring **142**, **143**
- water-soluble vitamins **234**  
weight gain and obesity  
adverse drug effects 210–213, 213  
pharmacological strategies **217**, **218**
- Wilder's law 93  
*Withania somnifera*, cognitive function 491  
withdrawal effects; *see also* drug discontinuation  
abrupt cessation of drugs 172  
addiction 426  
alcohol use/dependence 428–429  
withdrawal syndromes 172  
within-group effect sizes, research studies 53  
working memory 335, **498**, **499**
- xenobiotics 161  
xerostomia, adverse drug effects 199
- Yerkes–Dodson law, anxiety disorders 400  
yi-gan san (Chinese herbal medicine) 476  
yohimbe, adverse drug effects **216**  
yohimbine, serotonin receptor binding affinities **408**
- Z-drugs 403, 488; *see also* zolpidem  
zero order kinetics 131–132

## INDEX

- zinc supplements **236**
- ziprasidone
  - $\alpha$  receptor binding affinities **196**
  - antidepressant augmentation/adjuncts **325**
  - anxiety disorders **423–424**
  - bipolar disorder **332**
  - borderline personality disorder **483–484**
  - dopamine receptor binding affinities **204**
  - dosage conversions **185**
  - dosing recommendations **385**
  - hepatically impaired patients **274**
  - high-dosing regimes **381**
  - histamine receptor binding affinities **205, 212**
  - negative symptoms **398–399**
  - renal patients **277**
  - serotonin receptor binding affinities **212–213, 290, 408, 490**
  - short-acting intramuscular injection **367–368**
  - therapeutic drug monitoring **143, 148**
  - trauma/PTSD **464**
- zolpidem
  - hepatically impaired patients **274**
  - protein binding **262**
  - sex differences **247**
  - therapeutic drug monitoring **143**